Anti-il-13 antibodies and methods of use thereof

Abstract

The present application provides anti-IL-13 antibodies and antigen binding fragments thereof. Such antibodies and antigen binding fragments thereof may be used in methods for the treatment and / or prevention of an immunological disease or disorder.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present application claims the benefit of and priority to United States Provisional Application No. 63 / 618,322, filed on January 6, 2024, and United States Provisional Application No. 63 / 626,442, filed on January 29, 2024, both of which are incorporated herein by reference in their entirety. FIELD

[0002] Provided herein are antibodies and antigen binding fragments thereof that bind to interleukin-13 (IL-13). SEQUENCE LISTING

[0003] This application contains a sequence listing, which has been submitted in XML format via Patent Center. The contents of the XML copy named “134524-5008_Sequence_Listing_v5,” which was created on December 23, 2024, and is 295,766 bytes in size, are incorporated herein by reference in their entirety. INCORPORATION BY REFERENCE OF MATERIAL IN AN ASCII FILE

[0004] Without limiting the foregoing, this application incorporates by reference the code of respective Appendices A and B. This application incorporates by reference the Computer Program Listing contained in the following ASCII file being submitted concurrently herewith: a) File name: score.py; uploaded December 23, 2024 and available at https: / / zenodo.org / records / 14549062                    or                    at https: / / doi.org / 10.5281 / zenodo.14549062 and selecting “score.py”, 3,975 Bytes in size. The entire teachings of the above file are incorporated herein by reference in their entirety. b) File name: model.etab; uploaded December 23, 2024 and available at https: / / zenodo.org / records / 14549062                    or                    at https: / / doi.org / 10.5281 / zenodo.14549062 and selecting “model.etab”, 3,500,928 Bytes in size. The entire teachings of the above file are incorporated herein by reference in their entirety.

[0005] The entire teachings of the above files are incorporated herein by reference in their entirety. The script in score.py is intended to be run in a Python environment in the same folder as model.etab to use the data of model.etab. BACKGROUND

[0006] IL-13 (also known as Interleukin-13 or NC30) is a cytokine protein which is produced by immune cells such as T helper type 2 (Th2) cells (see, e.g., Rael and Lockey, World Allergy Organ J. 4:54-64; 2011). It is largely found in the extracellular matrix and regulates physiological cellular changes related to allergic inflammation across many tissues (see, e.g., Minty et al., Nature. 362:248-250; 1993).

[0007] IL-13 plays many immunological roles in the cell. For example, it stimulates B cell proliferation and is involved in the activation of other immune cells including eosinophils, basophils, and mast cells (see, e.g., Defrance etal., J Exp Med. 179:135-143; 1994; Luttmann et al., J Immunol. 157:1678-1683; 1996). Importantly, IL-13 contributes to IgE synthesis from activated B cells, wherein high levels of IgE antibodies are characteristic of parasitic infection or an allergic response (see, e.g., Punnonen et al., J Allergy Clin Immunol. 100(6):792-801; 1997).

[0008] IL-13 is considered to be a key driver of inflammation in conditions such as atopic dermatitis where it is found to be notably overexpressed in skin lesions. Despite development of treatments for IL-13 mediated diseases and disorders such treatments are inefficacious due to requirement for repeated dosing every 2-4 weeks resulting in lack of patient compliance to course of maintenance therapy. Accordingly, a need exists for additional therapeutics that offer extended dosing frequency as a means to improve patient compliance and response to course of treatment. SUMMARY

[0009] Described herein, inter alia, are binding molecules {e.g., proteins), such as antibodies or antigen binding fragments thereof that bind to IL-13; nucleic acids encoding such binding molecules; methods for using and preparing such binding molecules; pharmaceutical compositions that comprise such binding molecules, for prophylactic, therapeutic or diagnostic purposes; and methods of treating disease or disorders that comprise administering the binding molecules to a subject in need thereof.

[0010] In some aspects, described herein are anti-IL-13 antibodies or antigen binding fragments thereof comprising: i) a light chain variable region comprising SEQ ID NO: 1 (LCDR1), SEQ ID NO: 2 (LCDR2), and SEQ ID NO: 3 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 4 (HCDR1), SEQ ID NO: 5 (HCDR2), and SEQ ID NO: 6 (HCDR3); ii) a light chain variable region comprising SEQ ID NO: 7 (LCDR1), SEQ ID NO: 8 (LCDR2), and SEQ ID NO: 9 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 10 (HCDR1), SEQ ID NO: 11 (HCDR2), and SEQ ID NO: 12 (HCDR3); iii) a light chain variable region comprising SEQ ID NO: 13 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 15 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 16 (HCDR1), SEQ ID NO: 17 (HCDR2), and SEQ ID NO: 18 (HCDR3); iv) a light chain variable region comprising SEQ ID NO: 19 (LCDR1), SEQ ID NO: 20 (LCDR2), and SEQ ID NO: 21 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 22 (HCDR1), SEQ ID NO: 23 (HCDR2), and SEQ ID NO: 24 (HCDR3); v) a light chain variable region comprising SEQ ID NO: 25 (LCDR1), SEQ ID NO: 26 (LCDR2), and SEQ ID NO: 27 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3); vi) a light chain variable region comprising SEQ ID NO: 31 (LCDR1), SEQ ID NO: 32 (LCDR2), and SEQ ID NO: 33 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 34 (HCDR1), SEQ ID NO: 35 (HCDR2), and SEQ ID NO: 36 (HCDR3); vii) a light chain variable region comprising SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2), and SEQ ID NO: 39 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 40 (HCDR1), SEQ ID NO: 41 (HCDR2), and SEQ ID NO: 42 (HCDR3); viii) a light chain variable region comprising SEQ ID NO: 43 (LCDR1), SEQ ID NO: 44 (LCDR2), and SEQ ID NO: 45 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 46 (HCDR1), SEQ ID NO: 47 (HCDR2), and SEQ ID NO: 48 (HCDR3); ix) a light chain variable region comprising SEQ ID NO: 49 (LCDR1), SEQ ID NO: 50 (LCDR2), and SEQ ID NO: 51 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 52 (HCDR1), SEQ ID NO: 53 (HCDR2), and SEQ ID NO: 54 (HCDR3); x) a light chain variable region comprising SEQ ID NO: 55 (LCDR1), SEQ ID NO: 56 (LCDR2), and SEQ ID NO: 57 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 58 (HCDR1), SEQ ID NO: 59 (HCDR2), and SEQ ID NO: 60 (HCDR3); xi) a light chain variable region comprising SEQ ID NO: 61 (LCDR1), SEQ ID NO: 62 (LCDR2), and SEQ ID NO: 63 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 64 (HCDR1), SEQ ID NO: 65 (HCDR2), and SEQ ID NO: 66 (HCDR3); xii) a light chain variable region comprising SEQ ID NO: 67 (LCDR1), SEQ ID NO: 68 (LCDR2), and SEQ ID NO: 69 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 70 (HCDR1), SEQ ID NO: 71 (HCDR2), and SEQ ID NO: 72 (HCDR3); xiii) a light chain variable region comprising SEQ ID NO: 73 (LCDR1), SEQ ID NO: 74 (LCDR2), and SEQ ID NO: 75 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 76 (HCDR1), SEQ ID NO: 77 (HCDR2), and SEQ ID NO: 78 (HCDR3); xiv) a light chain variable region comprising SEQ ID NO: 79 (LCDR1), SEQ ID NO: 80 (LCDR2), and SEQ ID NO: 81 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 82 (HCDR1), SEQ ID NO: 83 (HCDR2), and SEQ ID NO: 84 (HCDR3); xv) a light chain variable region comprising SEQ ID NO: 85 (LCDR1), SEQ ID NO: 86 (LCDR2), and SEQ ID NO: 87 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 88 (HCDR1), SEQ ID NO: 89 (HCDR2), and SEQ ID NO: 90 (HCDR3); or xvi) a light chain variable region comprising SEQ ID NO: 91 (LCDR1), SEQ ID NO: 92 (LCDR2), and SEQ ID NO: 93 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 94 (HCDR1), SEQ ID NO: 95 (HCDR2), and SEQ ID NO: 96 (HCDR3).

[0011] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof comprise a light chain variable region comprising an amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and / or a heavy chain variable region comprising an amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0012] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof comprise a light chain variable region comprising an amino acid sequence that is about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and / or a heavy chain variable region comprising an amino acid sequence that is about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0013] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof comprise a light chain variable region comprising an amino acid sequence as set forth in SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and / or a heavy chain variable region comprising an amino acid sequence as set forth in SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0014] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof comprise: i) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 97, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 98; ii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 99, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 100; iii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 101, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 102; vi) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 103, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 104; v) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 105, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 106; vi) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 107, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 108; vii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 109, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 110; vii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 111, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEO. ID NO: 112; ix) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 113, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 114; x) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 115, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 116; xi) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 117, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 118; xii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 119, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 120; xiii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 121, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 122; xiv) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 123, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 124; xv) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 125, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 126; or xvi) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 127, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 128.

[0015] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof comprise a light chain comprising an amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0016] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof comprise a light chain comprising an amino acid sequence that is about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 129, 131, 133,135,137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence that is about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0017] in some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof comprises a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or211.

[0018] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof comprise: i) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 129, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 130; ii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 131, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 132; iii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 133, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 134; iv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 135, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 136; v) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 137, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 138; vi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 139, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 140; vii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 142; viii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 143, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 144; ix) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 145, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 146; x) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 148; xi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 149, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 150; xii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 151, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 152; xiii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 154; xiv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 155, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 156; xv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 157, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 158; xvi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 159, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 160; xvii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 182; xviii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 183; xix) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 184; xx) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 185; xxi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 186; xxii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 187; xxiii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 188; xxiv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 189; xxv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 190; xxvi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 191; xxvii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 192; xxviii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 193; xxix) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 194; xxx) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 195; xxxi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 196; xxxii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 197; xxxiii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 198; xxxiv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 199; xxxv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 200; xxxvi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 201; xxxvii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 202; xxxviii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 203; xxxix) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 204; xl) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 205; xli) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 206; xlii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 207; xliii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 208; xliv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 209; xlv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 210; orxlvi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 211.

[0019] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof are monoclonal antibodies.

[0020] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof are human antibodies.

[0021] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof are bispecific antibodies.

[0022] In some embodiments, the antigen binding fragment thereof is selected from the group consisting of: Fab, Fab’, F(ab’)2, Fd, Fv, scFv, a single-chain antibody, a minibody, and a diabody.

[0023] In some embodiments, the antigen binding fragments thereof is an scFv.

[0024] In some aspects, provided herein are anti-IL-13 antibodies or antigen binding fragments thereof used as a medicament.

[0025] In some aspects, provided herein is a pharmaceutical composition comprising anti-IL-13 antibodies or antigen binding fragments thereof and a pharmaceutically acceptable carrier.

[0026] In some aspects, provided herein is a nucleic acid composition comprising one or more nucleic acids encoding anti-IL-13 antibodies or antigen binding fragments thereof.

[0027] in some aspects, provided herein is an expression vector composition comprising one or more expression vectors comprising a nucleic acid composition as provided herein.

[0028] In some aspects, provided herein is a host cell comprising a nucleic acid composition or an expression vector composition as provided herein.

[0029] In some aspects, provided herein is a method for making anti-IL-13 antibodies or antigen binding fragments thereof comprising culturing the host cell as described herein under conditions where the anti-IL-13 antibodies or antigen binding fragments thereof are expressed and recovering the anti-l L-13 antibodies or binding fragments thereof.

[0030] in some aspects, also provided herein are anti-IL-13 antibodies or antigen binding fragments thereof comprising: a1) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 1 (LCDR1), SEQ ID NO: 2 (LCDR2), and SEQ ID NO: 3 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 4 (HCDR1), SEQ ID NO: 5 (HCDR2), and SEQ ID NO: 6 (HCDR3); a2) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 7 (LCDR1), SEQ ID NO: 8 (LCDR2), and SEQ ID NO: 9 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 10 (HCDR1), SEQ ID NO: 11 (HCDR2), and SEQ ID NO: 12 (HCDR3); a3) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 13 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 15 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 16 (HCDR1), SEQ ID NO: 17 (HCDR2), and SEQ ID NO: 18 (HCDR3); a4) light chain CDRs comprising amino acid sequences 10 that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 19 (LCDR1), SEQ ID NO: 20 (LCDR2), and SEQ ID NO: 21 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 22 (HCDR1), SEQ ID NO: 23 (HCDR2), and SEQ ID NO: 24 (HCDR3); a5) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 25 (LCDR1), SEQ ID NO: 26 (LCDR2), and SEQ ID NO: 27 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3); a6) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 31 (LCDR1), SEQ ID NO: 32 (LCDR2), and SEQ ID NO: 33 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 34 (HCDR1), SEQ ID NO: 35 (HCDR2), and SEQ ID NO: 36 (HCDR3); a7) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2), and SEQ ID NO: 39 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 40 (HCDR1), SEQ ID NO: 41 (HCDR2), and SEQ ID NO: 42 (HCDR3); a8) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 43 (LCDR1), SEQ ID NO: 44 (LCDR2), and SEQ ID NO: 45 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 46 (HCDR1), SEQ ID NO: 47 (HCDR2), and SEQ ID NO: 48 (HCDR3); a9) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 49 (LCDR1), SEQ ID NO: 50 (LCDR2), and SEQ ID NO: 51 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 52 (HCDR1), SEQ ID NO: 53 (HCDR2), and SEQ ID NO: 54 (HCDR3); a10) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 55 (LCDR1), SEQ ID NO: 56 (LCDR2), and SEQ ID NO: 57 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 58 (HCDR1), SEQ ID NO: 59 (HCDR2), and SEQ ID NO: 60 (HCDR3); a11) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 61 (LCDR1), SEQ ID NO: 62 (LCDR2), and SEQ ID NO: 63 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 64 (HCDR1), SEQ ID NO: 65 (HCDR2), and SEQ ID NO: 66 (HCDR3); a12) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 67 (LCDR1), SEQ ID NO: 68 (LCDR2), and SEQ ID NO: 69 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 70 (HCDR1), SEQ ID NO: 71 (HCDR2), and SEQ ID NO: 72 (HCDR3); a13) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 73 (LCDR1), SEQ ID NO: 74 (LCDR2), and SEQ ID NO: 75 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 76 (HCDR1), SEQ ID NO: 77 (HCDR2), and SEQ ID NO: 78 (HCDR3); a14) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 79 (LCDR1), SEQ ID NO: 80 (LCDR2), and SEQ ID NO: 81 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 82 (HCDR1), SEQ ID NO: 83 (HCDR2), and SEQ ID NO: 84 (HCDR3); a15) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 85 (LCDR1), SEQ ID NO: 86 (LCDR2), and SEQ ID NO: 87 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 88 (HCDR1), SEQ ID NO: 89 (HCDR2), and SEQ ID NO: 90 (HCDR3); or a16) light chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 91 (LCDR1), SEQ ID NO: 92 (LCDR2), and SEQ ID NO: 93 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 94 (HCDR1), SEQ ID NO: 95 (HCDR2), and SEQ ID NO: 96 (HCDR3); or b1) a light chain variable region comprising an amino acid sequence at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and b2) a heavy chain variable region comprising an amino acid sequence at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128, wherein the LCDR1 does not include SEQ ID NO: 162 (RASKSVDSYGNSFMH).

[0031] In some aspects, also provided herein are anti-IL-13 antibodies or antigen binding fragments thereof comprising: a1) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 1 (LCDR1), SEQ ID NO: 2 (LCDR2), and SEQ ID NO: 3 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 4 (HCDR1), SEQ ID NO: 5 (HCDR2), and SEQ ID NO: 6 (HCDR3); a2) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 7 (LCDR1), SEQ ID NO: 8 (LCDR2), and SEQ ID NO: 9 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 10 (HCDR1), SEQ ID NO: 11 (HCDR2), and SEQ ID NO: 12 (HCDR3); a3) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 13 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 15 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 16 (HCDR1), SEQ ID NO: 17 (HCDR2), and SEQ ID NO: 18 (HCDR3); a4) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 19 (LCDR1), SEQ ID NO: 20 (LCDR2), and SEQ ID NO: 21 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 22 (HCDR1), SEQ ID NO: 23 (HCDR2), and SEQ ID NO: 24 (HCDR3); a5) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 25 (LCDR1), SEQ ID NO: 26 (LCDR2), and SEQ ID NO: 27 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3); a6) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 31 (LCDR1), SEQ ID NO: 32 (LCDR2), and SEQ ID NO: 33 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 34 (HCDR1), SEQ ID NO: 35 (HCDR2), and SEQ ID NO: 36 (HCDR3); a7) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2), and SEQ ID NO: 39 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 40 (HCDR1), SEQ ID NO: 41 (HCDR2), and SEQ ID NO: 42 (HCDR3); a8) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 43 (LCDR1), SEQ ID NO: 44 (LCDR2), and SEQ ID NO: 45 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 46 (HCDR1), SEQ ID NO: 47 (HCDR2), and SEQ ID NO: 48 (HCDR3); a9) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 49 (LCDR1), SEQ ID NO: 50 (LCDR2), and SEQ ID NO: 51 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 52 (HCDR1), SEQ ID NO: 53 (HCDR2), and SEQ ID NO: 54 (HCDR3); a10) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 55 (LCDR1), SEQ ID NO: 56 (LCDR2), and SEQ ID NO: 57 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 58 (HCDR1), SEQ ID NO: 59 (HCDR2), and SEQ ID NO: 60 (HCDR3); a11) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 61 (LCDR1), SEQ ID NO: 62 (LCDR2), and SEQ ID NO: 63 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 64 (HCDR1), SEQ ID NO: 65 (HCDR2), and SEQ ID NO: 66 (HCDR3); a12) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 67 (LCDR1), SEQ ID NO: 68 (LCDR2), and SEQ ID NO: 69 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 70 (HCDR1), SEQ ID NO: 71 (HCDR2), and SEQ ID NO: 72 (HCDR3); a13) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 73 (LCDR1), SEQ ID NO: 74 (LCDR2), and SEQ ID NO: 75 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 76 (HCDR1), SEQ ID NO: 77 (HCDR2), and SEQ ID NO: 78 (HCDR3); a14) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 79 (LCDR1), SEQ ID NO: 80 (LCDR2), and SEQ ID NO: 81 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 82 (HCDR1), SEQ ID NO: 83 (HCDR2), and SEQ ID NO: 84 (HCDR3); a15) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 85 (LCDR1), SEQ ID NO: 86 (LCDR2), and SEQ ID NO: 87 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 88 (HCDR1), SEQ ID NO: 89 (HCDR2), and SEQ ID NO: 90 (HCDR3); or a16) light chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 91 (LCDR1), SEQ ID NO: 92 (LCDR2), and SEQ ID NO: 93 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 94 (HCDR1), SEQ ID NO: 95 (HCDR2), and SEQ ID NO: 96 (HCDR3); or b1) a light chain variable region comprising an amino acid sequence about 90%, about 95%, or about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and b2) a heavy chain variable region comprising an amino acid sequence about 90%, about 95%, or about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128, wherein the LCDR1 does not include SEQ ID NO: 162 (RASKSVDSYGNSFMH).

[0032] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof comprise a LCDR1 comprising a serine (S) at amino acid position 27D and an arginine (R) at amino acid position 30; a LCDR1 comprising a tyrosine (Y) at amino acid position 27D and a histidine (H) at amino acid position 30; a LCDR1 comprising a tyrosine (Y) at amino acid position 27D and an asparagine (N) at amino acid position 30; or a LCDR1 comprises a serine (S) at amino acid position 27D and a tyrosine (Y) at amino acid position 32, wherein the amino acid positions are based on Kabat numbering.

[0033] In some aspects, also provided herein are anti-IL-13 antibodies or antigen binding fragments thereof comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region is at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 97, 99, 101, and 103; wherein the heavy chain variable region is at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 98, 100, 102, and 104, provided that when serine (S) is present at amino acid position 27D then arginine (R) is present at amino acid position 30 or tyrosine (Y) is present at amino acid position 32, and when asparagine (N) is present at amino acid position 30 then tyrosine (Y) is present at amino acid position 27D, and wherein the amino acid positions are based on Kabat numbering.

[0034] In some aspects, also provided herein are anti-IL-13 antibodies or antigen binding fragments thereof comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region is about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 97, 99, 101, and 103; wherein the heavy chain variable region is about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 98, 100, 102, and 104, provided that when serine (S) is present at amino acid position 27D then arginine (R) is present at amino acid position 30 or tyrosine (Y) is present at amino acid position 32, and when asparagine (N) is present at amino acid position 30 then tyrosine (Y) is present at amino acid position 27D, and wherein the amino acid positions are based on Kabat numbering.

[0035] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof are monoclonal antibodies.

[0036] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof are human antibodies.

[0037] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof are bispecific antibodies.

[0038] In some embodiments, the antigen binding fragment thereof is selected from the group consisting of: Fab, Fab’, F(ab’)z, Fd, Fv, scFv, a single-chain antibody, a minibody, and a diabody.

[0039] In some embodiments, the antigen binding fragment thereof is an scFv.

[0040] In some aspects, provided herein are anti-IL-13 antibodies or antigen binding fragments thereof used as a medicament.

[0041] In some aspects, provided herein is a pharmaceutical composition comprising anti-IL-13 antibodies or an antigen binding fragments thereof and a pharmaceutically acceptable carrier.

[0042] In some aspects, provided herein is a nucleic acid composition comprising one or more nucleic acids encoding anti-IL-13 antibodies or antigen binding fragments thereof.

[0043] In some aspects, provided herein is an expression vector composition comprising one or more expression vectors comprising a nucleic acid composition as provided herein.

[0044] In some aspects, provided herein is a host cell comprising a nucleic acid composition or an expression vector composition as provided herein.

[0045] In some aspects, provided herein is a method for making anti-IL-13 antibodies or antigen binding fragments thereof comprising culturing the host cell as described herein under conditions where the anti-IL-13 antibodies or binding fragments thereof are expressed and recovering the anti-IL-13 antibodies or binding fragments thereof.

[0046] In some aspects, described herein is a method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective dose of anti-IL-13 antibodies or antigen binding fragments thereof, wherein the anti-IL-13 antibodies or antigen binding fragments thereof comprise: i) a light chain variable region comprising SEQ ID NO: 1 (LCDR1), SEQ ID NO: 2 (LCDR2), and SEQ ID NO: 3 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 4 (HCDR1), SEQ ID NO: 5 (HCDR2), and SEQ ID NO: 6 (HCDR3): ii) a light chain variable region comprising SEQ ID NO: 7 (LCDR1), SEQ ID NO: 8 (LCDR2), and SEQ ID NO: 9 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 10 (HCDR1), SEQ ID NO: 11 (HCDR2), and SEQ ID NO: 12 (HCDR3); Hi) a light chain variable region comprising SEQ ID NO: 13 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 15 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 16 (HCDR1), SEQ ID NO: 17 (HCDR2), and SEQ ID NO: 18 (HCDR3); iv) a light chain variable region comprising SEQ ID NO: 19 (LCDR1), SEQ ID NO: 20 (LCDR2), and SEQ ID NO: 21 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 22 (HCDR1), SEQ ID NO: 23 (HCDR2), and SEQ ID NO: 24 (HCDR3); v) a light chain variable region comprising SEQ ID NO: 25 (LCDR1), SEQ ID NO: 26 (LCDR2); and SEQ ID NO: 27 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3); vi) a light chain variable region comprising SEQ ID NO: 31 (LCDR1), SEQ ID NO: 32 (LCDR2), and SEQ ID NO: 33 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 34 (HCDR1), SEQ ID NO: 35 (HCDR2), and SEQ ID NO: 36 (HCDR3); vii) a light chain variable region comprising SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2), and SEQ ID NO: 39 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 40 (HCDR1), SEQ ID NO: 41 (HCDR2), and SEQ ID NO: 42 (HCDR3); viii) a light chain variable region comprising SEQ ID NO: 43 (LCDR1), SEQ ID NO: 44 (LCDR2), and SEQ ID NO: 45 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 46 (HCDR1), SEQ ID NO: 47 (HCDR2), and SEQ ID NO: 48 (HCDR3); ix) a light chain variable region comprising SEQ ID NO: 49 (LCDR1), SEQ ID NO: 50 (LCDR2), and SEQ ID NO: 51 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 52 (HCDR1), SEQ ID NO: 53 (HCDR2), and SEQ ID NO: 54 (HCDR3); x) a light chain variable region comprising SEQ ID NO: 55 (LCDR1), SEQ ID NO: 56 (LCDR2), and SEQ ID NO: 57 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 58 (HCDR1), SEQ ID NO: 59 (HCDR2), and SEQ ID NO: 60 (HCDR3); xi) a light chain variable region comprising SEQ ID NO: 61 (LCDR1), SEQ ID NO: 62 (LCDR2), and SEQ ID NO: 63 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 64 (HCDR1), SEQ ID NO: 65 (HCDR2), and SEQ ID NO: 66 (HCDR3); xii) a light chain variable region comprising SEQ ID NO: 67 (LCDR1), SEQ ID NO: 68 (LCDR2), and SEQ ID NO: 69 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 70 (HCDR1), SEQ ID NO: 71 (HCDR2), and SEQ ID NO: 72 (HCDR3); xiii) a light chain variable region comprising SEQ ID NO: 73 (LCDR1), SEQ ID NO: 74 (LCDR2), and SEQ ID NO: 75 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 76 (HCDR1), SEQ ID NO: 77 (HCDR2), and SEQ ID NO: 78 (HCDR3); xiv) a light chain variable region comprising SEQ ID NO: 79 (LCDR1), SEQ ID NO: 80 (LCDR2), and SEQ ID NO: 81 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 82 (HCDR1), SEQ ID NO: 83 (HCDR2), and SEQ ID NO: 84 (HCDR3); xv) a light chain variable region comprising SEO. ID NO: 85 (LCDR1), SEQ ID NO: 86 (LCDR2), and SEQ ID NO: 87 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 88 (HCDR1), SEQ ID NO: 89 (HCDR2), and SEQ ID NO: 90 (HCDR3); orxvi) a light chain variable region comprising SEQ ID NO: 91 (LCDR1), SEQ ID NO: 92 (LCDR2), and SEQ ID NO: 93 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 94 (HCDR1), SEQ ID NO: 95 (HCDR2), and SEQ ID NO: 96 (HCDR3).

[0047] In some embodiments, the disease or disorder is selected from the group consisting of: asthma (including, but not limited to, mild asthma, mild to moderate asthma, moderate asthma, moderate to severe asthma, and / or severe asthma), allergic asthma, allergen-induced airway obstruction due to asthma and / or allergic asthma, atopic dermatitis (including, but not limited to, mild atopic dermatitis, mild to moderate atopic dermatitis, moderate atopic dermatitis, moderate-to-severe, and / or severe atopic dermatitis), eczema, acute urticaria, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (CORD), chronic obstructive airway disease, emphysema, chronic bronchitis, pulmonary fibrosis, systemic sclerosis, scleroderma, cryptogenic fibrosing alveolitis, usual interstitial pneumonitis, idiopathic interstitial pneumonitis, wound, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SS), ulcerative colitis (UC), type 1 diabetes (T1D), sjogren's syndrome (SS), prurigo nodularis, nasal polyposis, recurrent urticaria, aspergillosis, bullous pemphigoid, chronic sinusitis, alopecia areata, hay fever, pemphigus, allergic rhinitis, psoriasis, rosacea, allergic drug reactions, allergic reactions, anaphylaxis, acne, food allergies, inflammatory bowel disease (IBS), Crohn’s disease, ulcerative colitis, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis, eosinophilic colitis, eosinophilic gastritis, eosinophilic cystitis, eosinophilic fasciitis, eosinophilic pustular folliculitis, eosinophilic granulomatosis, eosinophilic polyangiitis, Churg-Strauss syndrome, biliary cancer, brain cancer, breast cancer, colorectal cancer, genitourinary cancer, head and neck cancer, liver cancer, Hodgkin's lymphoma, esophageal cancer, pancreatic cancer, prostate cancer, renal cancer, Kaposi's sarcoma, sinusitis, or chronic urticaria.

[0048] In some embodiments, the light chain variable region comprises an amino acid sequence that is at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or127; and the heavy chain variable region comprises an amino acid sequence that is at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0049] In some embodiments, the light chain variable region comprises an amino acid sequence that is about 90%, about 95%, or about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and the heavy chain variable region comprises an amino acid sequence that is about 90%, about 95%, or about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0050] In some embodiments, the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and / or the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0051] In some embodiments, the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 97, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 98; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 99, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 100; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 101, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 102; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 103, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 104; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 105, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 106; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 107, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 108; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 109, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 110; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 111, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 112; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 113, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 114; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 115, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 116; the light chain variable region comprises an amino acid sequence as set forth 19 in SEQ ID NO: 117, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 118; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 119, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 120; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 121, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 122; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 123, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 124; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 125, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 126; or the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 127, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 128.

[0052] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof comprise a light chain comprising an amino acid sequence that is at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence that is at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0053] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof comprise a light chain comprising an amino acid sequence that is about 90%, about 95%, or about 99% identical to SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence that is about 90%, about 95%, or about 99% identical to SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201,202, 203, 204, 205, 206, 207, 208, 209, 210, or211.

[0054] In some embodiments, the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0055] In some embodiments, the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 129, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 130; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 131, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 132; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 133, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 134; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 135, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 136; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 137, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 138; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 139, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 140; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 142; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 143, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 144; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 145, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 146; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 148; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 149, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 150; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 151, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 152; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 154; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 155, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 156; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 157, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 158; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 159, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 160; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 182; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 183; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 184; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 185; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 186; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 187; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 188; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 189; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 190; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 191; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 192; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 193; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 194; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 195; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 196; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 197; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 198; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 199; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 200; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 201; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 202; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 203; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 204; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 205; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 206; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 207; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 208; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 209; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 210; or the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 211.

[0056] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof are monoclonal antibodies.

[0057] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof are human antibodies.

[0058] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof are bispecific antibodies.

[0059] In some embodiments, the antigen binding fragment thereof is selected from the group consisting of Fab, Fab’, F(ab’)2, Fd, Fv, scFv, a single-chain antibody, a minibody, and a diabody.

[0060] In some embodiments, the antigen binding fragment thereof is an scFv.

[0061] In some aspects, described herein are antibodies or antigen binding fragments thereof comprising: i) a light chain variable region comprising SEQ ID NO: 1 (LCDR1), SEQ ID NO: 2 (LCDR2), and SEQ ID NO: 3 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 4 (HCDR1), SEQ ID NO: 5 (HCDR2), and SEQ ID NO: 6 (HCDR3); ii) a light chain variable region comprising SEQ ID NO: 7 (LCDR1), SEQ ID NO: 8 (LCDR2), and SEQ ID NO: 9 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 10 (HCDR1), SEQ ID NO: 11 (HCDR2), and SEQ ID NO: 12 (HCDR3); iii) a light chain variable region comprising SEQ ID NO: 13 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 15 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 16 (HCDR1), SEQ ID NO: 17 (HCDR2), and SEQ ID NO: 18 (HCDR3); iv) a light chain variable region comprising SEQ ID NO: 19 (LCDR1), SEQ ID NO: 20 (LCDR2), and SEQ ID NO: 21 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 22 (HCDR1), SEQ. ID NO: 23 (HCDR2), and SEQ ID NO: 24 (HCDR3); v) a light chain variable region comprising SEQ ID NO: 25 (LCDR1), SEQ ID NO: 26 (LCDR2), and SEQ ID NO: 27 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3); vi) a light chain variable region comprising SEQ ID NO: 31 (LCDR1), SEQ ID NO: 32 (LCDR2), and SEQ ID NO: 33 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 34 (HCDR1), SEQ ID NO: 35 (HCDR2), and SEQ ID NO: 36 (HCDR3); vii) a light chain variable region comprising SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2), and SEQ ID NO: 39 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 40 (HCDR1), SEQ ID NO: 41 (HCDR2), and SEQ ID NO: 42 (HCDR3); viii) a light chain variable region comprising SEQ ID NO: 43 (LCDR1), SEQ ID NO: 44 (LCDR2), and SEQ ID NO: 45 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 46 (HCDR1), SEQ ID NO: 47 (HCDR2), and SEQ ID NO: 48 (HCDR3); ix) a light chain variable region comprising SEQ ID NO: 49 (LCDR1), SEQ ID NO: 50 (LCDR2), and SEQ ID NO: 51 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 52 (HCDR1), SEQ ID NO: 53 (HCDR2), and SEQ ID NO: 54 (HCDR3); x) a light chain variable region comprising SEQ ID NO: 55 (LCDR1), SEQ ID NO: 56 (LCDR2), and SEQ ID NO: 57 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 58 (HCDR1), SEQ ID NO: 59 (HCDR2), and SEQ ID NO: 60 (HCDR3); xi) a light chain variable region comprising SEQ ID NO: 61 (LCDR1), SEQ ID NO: 62 (LCDR2), and SEQ ID NO: 63 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 64 (HCDR1), SEQ ID NO: 65 (HCDR2), and SEQ ID NO: 66 (HCDR3); xii) a light chain variable region comprising SEQ ID NO: 67 (LCDR1), SEQ ID NO: 68 (LCDR2), and SEQ ID NO: 69 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 70 (HCDR1), SEQ ID NO: 71 (HCDR2), and SEQ ID NO: 72 (HCDR3); xiii) a light chain variable region comprising SEQ ID NO: 73 (LCDR1), SEQ ID NO: 74 (LCDR2), and SEQ ID NO: 75 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 76 (HCDR1), SEQ ID NO: 77 (HCDR2), and SEQ ID NO: 78 (HCDR3); xiv) a light chain variable region comprising SEQ ID NO: 79 (LCDR1), SEQ ID NO: 80 (LCDR2), and SEQ ID NO: 81 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 82 (HCDR1), SEQ ID NO: 83 (HCDR2), and SEQ ID NO: 84 (HCDR3); xv) a light chain variable region comprising SEQ ID NO: 85 (LCDR1), SEQ ID NO: 86 (LCDR2), and SEQ ID NO: 87 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 88 (HCDR1), SEQ ID NO: 89 (HCDR2), and SEQ ID NO: 90 (HCDR3); or xvi) a light chain variable region comprising SEQ ID NO: 91 (LCDR1), SEQ ID NO: 92 (LCDR2), and SEQ ID NO: 93 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 94 (HCDR1), SEQ ID NO: 95 (HCDR2), and SEQ ID NO: 96 (HCDR3).

[0062] In some embodiments, the antibodies or antigen binding fragments thereof comprise a light chain variable region comprising an amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and / or a heavy chain variable region comprising an amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0063] In some embodiments, the antibodies or antigen binding fragments thereof comprise a light chain variable region comprising an amino acid sequence that is about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and / or a heavy chain variable region comprising an amino acid sequence that is about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0064] In some embodiments, the antibodies or antigen binding fragments thereof comprise a light chain variable region comprising an amino acid sequence as set forth in SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and / or a heavy chain variable region comprising an amino acid sequence as set forth in SEQ ID NO: 98,100,102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0065] In some embodiments, the antibodies or antigen binding fragments thereof comprise: i) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 97, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 98; ii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 99, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 100; iii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 101, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 102; vi) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 103, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 104; v) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 105, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 106; vi) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 107, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 108; vii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 109, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 110; vii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 111, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 112; ix) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 113, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 114; x) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 115, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 116; xi) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 117, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 118; xii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 119, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 120; xiii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 121, and a heavy chain variable region comprising an amino add sequence as set forth in in SEQ ID NO: 122: xiv) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 123, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 124; xv) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 125, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 126; or xvi) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 127, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 128.

[0066] In some embodiments, the antibodies or antigen binding fragments thereof comprise a light chain comprising an amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0067] In some embodiments, the antibodies or antigen binding fragments thereof comprise a light chain comprising an amino acid sequence that is about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence that is about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0068] In some embodiments, the antibodies or antigen binding fragments thereof comprises a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201,202, 203, 204, 205, 206, 207, 208, 209, 210, or211.

[0069] In some embodiments, the antibodies or antigen binding fragments thereof comprise: I) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 129, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 130; ii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 131, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 132; iii) a light chain comprising an amino acid 27 sequence as set forth in SEQ ID NO: 133, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 134; iv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 135, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 136; v) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 137, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 138; vi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 139, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 140; vii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 142; viii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 143, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 144; ix) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 145, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 146; x) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 148; xi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 149, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 150; xii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 151, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 152; xiii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 154; xiv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 155, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 156; xv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 157, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 158; xvi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 159, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 160; xvii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 182; xviii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 183; xix) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 184; xx) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 185; xxi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 186; xxii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 187; xxiii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 188; xxiv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 189; xxv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 190; xxvi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 191; xxvii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 192; xxviii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 193; xxix) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 194; xxx) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 195; xxxi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 196; xxxii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 197; xxxiii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 198; xxxiv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 199; xxxv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 200; xxxvi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 201; xxxvii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 202; xxxviii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 203; xxxix) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 204; xl) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 205; xli) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 206; xlii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 207; xliii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 208; xliv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 209; xlv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 210; orxlvi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 211.

[0070] In some embodiments, the antibodies or antigen binding fragments thereof are monoclonal antibodies.

[0071] In some embodiments, the antibodies or antigen binding fragments thereof are human antibodies.

[0072] In some embodiments, the antibodies or antigen binding fragments thereof are bispecific antibodies.

[0073] In some embodiments, the antigen binding fragment thereof is selected from the group consisting of: Fab, Fab’, F(ab')2, Fd, Fv, scFv, a single-chain antibody, a minibody, and a diabody.

[0074] In some embodiments, the antigen binding fragments thereof is an scFv.

[0075] In some aspects, provided herein are antibodies or antigen binding fragments thereof used as a medicament.

[0076] In some aspects, provided herein is a pharmaceutical composition comprising antibodies or antigen binding fragments thereof and a pharmaceutically acceptable carrier.

[0077] In some aspects, provided herein is a nucleic acid composition comprising one or more nucleic acids encoding antibodies or antigen binding fragments thereof.

[0078] In some aspects, provided herein is an expression vector composition comprising one or more expression vectors comprising a nucleic acid composition as provided herein.

[0079] In some aspects, provided herein is a host cell comprising a nucleic acid composition or an expression vector composition as provided herein.

[0080] In some aspects, provided herein is a method for making anti-IL-13 antibodies or antigen binding fragments thereof comprising culturing the host cell as described herein under conditions where the anti-IL-13 antibodies or antigen binding fragments thereof are expressed and recovering the anti-IL-13 antibodies or binding fragments thereof.

[0081] in some aspects, also provided herein are antibodies or antigen binding fragments thereof comprising: a1) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 1 (LCDR1), SEQ ID NO: 2 (LCDR2), and SEQ ID NO: 3 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 4 (HCDR1), SEQ ID NO: 5 (HCDR2), and SEQ ID NO: 6 (HCDR3); a2) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 7 (LCDR1), SEQ ID NO: 8 (LCDR2), and SEQ ID NO: 9 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 10 (HCDR1), SEQ ID NO: 11 (HCDR2), and SEQ ID NO: 12 (HCDR3); a3) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 13 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 15 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 16 (HCDR1), SEQ ID NO: 17 (HCDR2), and SEQ ID NO: 18 (HCDR3); a4) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 19 (LCDR1), SEQ ID NO: 20 (LCDR2), and SEQ ID NO: 21 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 22 (HCDR1), SEQ ID NO: 23 (HCDR2), and SEQ ID NO: 24 (HCDR3); a5) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 25 (LCDR1), SEQ ID NO: 26 (LCDR2), and SEQ ID NO: 27 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 31 (HCDR2), and SEQ ID NO: 30 (HCDR3); a6) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 31 (LCDR1), SEQ ID NO: 32 (LCDR2), and SEQ ID NO: 33 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 34 (HCDR1), SEQ ID NO: 35 (HCDR2), and SEQ ID NO: 36 (HCDR3); a7) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2), and SEQ ID NO: 39 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 40 (HCDR1), SEQ ID NO: 41 (HCDR2), and SEQ ID NO: 42 (HCDR3); a8) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 43 (LCDR1), SEQ ID NO: 44 (LCDR2), and SEQ ID NO: 45 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 46 (HCDR1), SEQ ID NO: 47 (HCDR2), and SEQ ID NO: 48 (HCDR3); a9) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 49 (LCDR1), SEQ ID NO: 50 (LCDR2), and SEQ ID NO: 51 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 52 (HCDR1), SEQ ID NO: 53 (HCDR2), and SEQ ID NO: 54 (HCDR3); a10) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 55 (LCDR1), SEQ ID NO: 56 (LCDR2), and SEQ ID NO: 57 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 58 (HCDR1), SEQ ID NO: 59 (HCDR2), and SEQ ID NO: 60 (HCDR3); a11) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 61 (LCDR1), SEQ ID NO: 62 (LCDR2), and SEQ ID NO: 63 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 64 (HCDR1), SEQ ID NO: 65 (HCDR2), and SEQ ID NO: 66 (HCDR3); a12) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 67 (LCDR1), SEQ ID NO: 68 (LCDR2), and SEQ ID NO: 69 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 70 (HCDR1), SEQ ID NO: 71 (HCDR2), and SEQ ID NO: 72 (HCDR3); a13) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 73 (LCDR1), SEQ ID NO: 74 (LCDR2), and SEQ ID NO: 75 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 76 (HCDR1), SEQ ID NO: 77 (HCDR2), and SEQ ID NO: 78 (HCDR3); a14) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 79 (LCDR1), SEQ ID NO: 80 (LCDR2), and SEQ ID NO: 81 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 82 (HCDR1), SEQ ID NO: 83 (HCDR2), and SEQ ID NO: 84 (HCDR3); a15) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 85 (LCDR1), SEQ ID NO: 86 (LCDR2), and SEQ ID NO: 87 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 88 (HCDR1), SEQ ID NO: 89 (HCDR2), and SEQ ID NO: 90 (HCDR3); or a16) light chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 91 (LCDR1), SEQ ID NO: 92 (LCDR2), and SEQ ID NO: 93 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 94 (HCDR1), SEQ ID NO: 95 (HCDR2), and SEQ ID NO: 96 (HCDR3); or b1) a light chain variable region comprising an amino acid sequence at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and b2) a heavy chain variable region comprising an amino acid sequence at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128, wherein the LCDR1 does not include SEQ ID NO: 162 (RASKSVDSYGNSFMH).

[0082] In some aspects, also provided herein are antibodies or antigen binding fragments thereof comprising: a1) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 1 (LCDR1), SEQ ID NO: 2 (LCDR2), and SEQ ID NO: 3 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 4 (HCDR1), SEQ ID NO: 5 (HCDR2), and SEQ ID NO: 6 (HCDR3); a2) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 7 (LCDR1), SEQ ID NO: 8 (LCDR2), and SEQ ID NO: 9 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 10 (HCDR1), SEQ ID NO: 11 (HCDR2), and SEQ ID NO: 12 (HCDR3); a3) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 13 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 15 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 16 (HCDR1), SEQ ID NO: 17 (HCDR2), and SEQ ID NO: 18 (HCDR3); a4) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 19 (LCDR1), SEQ ID NO: 20 (LCDR2), and SEQ ID NO: 21 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 22 (HCDR1), SEQ ID NO: 23 (HCDR2), and SEQ ID NO: 24 (HCDR3); a5) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 25 (LCDR1), SEQ ID NO: 26 (LCDR2), and SEQ ID NO: 27 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3); a6) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 31 (LCDR1), SEQ ID NO: 32 (LCDR2), and SEQ ID NO: 33 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 34 (HCDR1), SEQ ID NO: 35 (HCDR2), and SEQ ID NO: 36 (HCDR3); a7) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2), and SEQ ID NO: 39 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 40 (HCDR1), SEQ ID NO: 41 (HCDR2), and SEQ ID NO: 42 (HCDR3); a8) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 43 (LCDR1), SEQ ID NO: 44 (LCDR2), and SEQ ID NO: 45 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 46 (HCDR1), SEQ ID NO: 47 (HCDR2), and SEQ ID NO: 48 (HCDR3); a9) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 49 (LCDR1), SEQ ID NO: 50 (LCDR2), and SEQ ID NO: 51 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 52 (HCDR1), SEQ ID NO: 53 (HCDR2), and SEQ ID NO: 54 (HCDR3); a10) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 55 (LCDR1), SEQ ID NO: 56 (LCDR2), and SEQ ID NO: 57 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 58 (HCDR1), SEQ ID NO: 59 (HCDR2), and SEQ ID NO: 60 (HCDR3); a11) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 61 (LCDR1), SEQ ID NO: 62 (LCDR2), and SEQ ID NO: 63 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 64 (HCDR1), SEQ ID NO: 65 (HCDR2), and SEQ ID NO: 66 (HCDR3); a12) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 67 (LCDR1), SEQ ID NO: 68 (LCDR2), and SEQ ID NO: 69 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 70 (HCDR1), SEQ ID NO: 71 (HCDR2), and SEQ ID NO: 72 (HCDR3); a13) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 73 (LCDR1), SEQ ID NO: 74 (LCDR2), and SEQ ID NO: 75 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 76 (HCDR1), SEQ ID NO: 77 (HCDR2), and SEQ ID NO: 78 (HCDR3); a14) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 79 (LCDR1), SEQ ID NO: 80 (LCDR2), and SEQ ID NO: 81 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 82 (HCDR1), SEQ ID NO: 83 (HCDR2), and SEQ ID NO: 84 (HCDR3); a15) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 85 (LCDR1), SEQ ID NO: 86 (LCDR2), and SEQ ID NO: 87 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 88 (HCDR1), SEQ ID NO: 89 (HCDR2), and SEQ ID NO: 90 (HCDR3); or a16) light chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 91 (LCDR1), SEQ ID NO: 92 (LCDR2), and SEQ ID NO: 93 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 94 (HCDR1), SEQ ID NO: 95 (HCDR2), and SEQ ID NO: 96 (HCDR3); or b1) a light chain variable region comprising an amino acid sequence about 90%, about 95%, or about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and b2) a heavy chain variable region comprising an amino acid sequence about 90%, about 95%, or about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128, wherein the LCDR1 does not include SEQ ID NO: 162 (RASKSVDSYGNSFMH).

[0083] In some embodiments, the antibodies or antigen binding fragments thereof comprise a LCDR1 comprising a serine (S) at amino acid position 27D and an arginine (R) at amino acid position 30; a LCDR1 comprising a tyrosine (Y) at amino acid position 27D and a histidine (H) at amino acid position 30; a LCDR1 comprising a tyrosine (Y) at amino acid position 27D and an asparagine (N) at amino acid position 30; or a LCDR1 comprises a serine (S) at amino acid position 27D and a tyrosine (Y) at amino acid position 32, wherein the amino acid positions are based on Kabat numbering.

[0084] In some aspects, also provided herein are antibodies or antigen binding fragments thereof comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region is at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 97, 99, 101, and 103; wherein the heavy chain variable region is at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 98, 100, 102, and 104, provided that when serine (S) is present at amino acid position 27D then arginine (R) is present at amino acid position 30 or tyrosine (Y) is present at amino acid position 32, and when asparagine (N) is present at amino acid position 30 then tyrosine (Y) is present at amino acid position 27D, and wherein the amino acid positions are based on Kabat numbering.

[0085] In some aspects, also provided herein are antibodies or antigen binding fragments thereof comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region is about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 97, 99, 101, and 103: wherein the heavy chain variable region is about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 98, 100, 102, and 104, provided that when serine (S) is present at amino acid position 27D then arginine (R) is present at amino acid position 30 or tyrosine (Y) is present at amino acid position 32, and when asparagine (N) is present at amino acid position 30 then tyrosine (Y) is present at amino acid position 27D, and wherein the amino acid positions are based on Kabat numbering.

[0086] In some embodiments, the antibodies or antigen binding fragments thereof are monoclonal antibodies.

[0087] In some embodiments, the antibodies or antigen binding fragments thereof are human antibodies.

[0088] In some embodiments, the antibodies or antigen binding fragments thereof are bispecific antibodies.

[0089] In some embodiments, the antigen binding fragment thereof is selected from the group consisting of: Fab, Fab’, F(ab’)2, Fd, Fv, scFv, a single-chain antibody, a minibody, and a diabody.

[0090] In some embodiments, the antigen binding fragment thereof is an scFv.

[0091] In some aspects, provided herein are antibodies or antigen binding fragments thereof used as a medicament.

[0092] In some aspects, provided herein is a pharmaceutical composition comprising antibodies or an antigen binding fragments thereof and a pharmaceutically acceptable carrier.

[0093] In some aspects, provided herein is a nucleic acid composition comprising one or more nucleic acids encoding antibodies or antigen binding fragments thereof.

[0094] In some aspects, provided herein is an expression vector composition comprising one or more expression vectors comprising a nucleic acid composition as provided herein.

[0095] In some aspects, provided herein is a host cell comprising a nucleic acid composition or an expression vector composition as provided herein.

[0096] In some aspects, provided herein is a method for making anti-IL-13 antibodies or antigen binding fragments thereof comprising culturing the host cell as described herein under conditions where the anti-IL-13 antibodies or antigen binding fragments thereof are expressed and recovering the anti-IL-13 antibodies or binding fragments thereof.

[0097] In some aspects, described herein is a method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective dose of antibodies or antigen binding fragments thereof, wherein the antibodies or antigen binding fragments thereof comprise: i) a light chain variable region comprising SEQ ID NO: 1 (LCDR1), SEQ ID NO: 2 (LCDR2), and SEQ ID NO: 3 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 4 (HCDR1), SEQ ID NO: 5 (HCDR2), and SEQ ID NO: 6 (HCDR3); ii) a light chain variable region comprising SEQ ID NO: 7 (LCDR1), SEQ ID NO: 8 (LCDR2), and SEQ ID NO: 9 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 10 (HCDR1), SEQ ID NO: 11 (HCDR2), and SEQ ID NO: 12 (HCDR3): ill) a light chain variable region comprising SEQ ID NO: 13 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 15 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 16 (HCDR1), SEQ ID NO: 17 (HCDR2), and SEQ ID NO: 18 (HCDR3); iv) a light chain variable region comprising SEQ ID NO: 19 (LCDR1), SEQ ID NO: 20 (LCDR2), and SEQ ID NO: 21 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 22 (HCDR1), SEQ ID NO: 23 (HCDR2), and SEQ ID NO: 24 (HCDR3); v) a light chain variable region comprising SEQ ID NO: 25 (LCDR1), SEQ ID NO: 26 (LCDR2), and SEQ ID NO: 27 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3); vi) a light chain variable region comprising SEQ ID NO: 31 (LCDR1), SEQ ID NO: 32 (LCDR2), and SEQ ID NO: 33 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 34 (HCDR1), SEQ ID NO: 35 (HCDR2), and SEQ ID NO: 36 (HCDR3); vii) a light chain variable region comprising SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2), and SEQ ID NO: 39 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 40 (HCDR1), SEQ ID NO: 41 (HCDR2), and SEQ ID NO: 42 (HCDR3); viii) a light chain variable region comprising SEQ ID NO: 43 (LCDR1), SEQ ID NO: 44 (LCDR2), and SEQ ID NO: 45 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 46 (HCDR1), SEQ ID NO: 47 (HCDR2), and SEQ ID NO: 48 (HCDR3); ix) a light chain variable region comprising SEQ ID NO: 49 (LCDR1), SEQ ID NO: 50 (LCDR2), and SEQ ID NO: 51 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 52 (HCDR1), SEQ ID NO: 53 (HCDR2), and SEQ ID NO: 54 (HCDR3); x) a light chain variable region comprising SEQ ID NO: 55 (LCDR1), SEQ ID NO: 56 (LCDR2), and SEQ ID NO: 57 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 58 (HCDR1), SEQ ID NO: 59 (HCDR2), and SEQ ID NO: 60 (HCDR3); xi) a light chain variable region comprising SEQ ID NO: 61 (LCDR1), SEQ ID NO: 62 (LCDR2), and SEQ ID NO: 63 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 64 (HCDR1), SEQ ID NO: 65 (HCDR2), and SEQ ID NO: 66 (HCDR3); xii) a light chain variable region comprising SEQ ID NO: 67 (LCDR1), SEQ ID NO: 68 (LCDR2), and SEQ ID NO: 69 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 70 (HCDR1), SEQ ID NO: 71 (HCDR2), and SEQ ID NO: 72 (HCDR3); xiii) a light chain variable region comprising SEQ ID NO: 73 (LCDR1), SEQ ID NO: 74 (LCDR2), and SEQ ID NO: 75 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 76 (HCDR1), SEQ ID NO: 77 (HCDR2), and SEQ ID NO: 78 (HCDR3); xiv) a light chain variable region comprising SEQ ID NO: 79 (LCDR1), SEQ ID NO: 80 (LCDR2), and SEQ ID NO: 81 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 82 (HCDR1), SEQ ID NO: 83 (HCDR2), and SEQ ID NO: 84 (HCDR3); xv) a light chain variable region comprising SEQ ID NO: 85 (LCDR1), SEQ ID NO: 86 (LCDR2), and SEQ ID NO: 87 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 88 (HCDR1), SEQ ID NO: 89 (HCDR2), and SEQ ID NO: 90 (HCDR3); or xvi) a light chain variable region comprising SEQ ID NO: 91 (LCDR1), SEQ ID NO: 92 (LCDR2), and SEQ ID NO: 93 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 94 (HCDR1), SEQ ID NO: 95 (HCDR2), and SEQ ID NO: 96 (HCDR3).

[0098] In some embodiments, the disease or disorder is selected from the group consisting of: asthma (including, but not limited to, mild asthma, mild to moderate asthma, moderate asthma, moderate to severe asthma, and / or severe asthma), allergic asthma, allergen-induced airway obstruction due to asthma and / or allergic asthma, atopic dermatitis (including, but not limited to, mild atopic dermatitis, mild to moderate atopic dermatitis, moderate atopic dermatitis, moderate-to-severe, and / or severe atopic dermatitis), eczema, acute urticaria, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), chronic obstructive airway disease, emphysema, chronic bronchitis, pulmonary fibrosis, systemic sclerosis, scleroderma, cryptogenic fibrosing alveolitis, usual interstitial pneumonitis, idiopathic interstitial pneumonitis, wound, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SS), ulcerative colitis (UC), type 1 diabetes (T1D), sjogren's syndrome (SS), prurigo nodularis, nasal polyposis, recurrent urticaria, aspergillosis, bullous pemphigoid, chronic sinusitis, alopecia areata, hay fever, pemphigus, allergic rhinitis, psoriasis, rosacea, allergic drug reactions, allergic reactions, anaphylaxis, acne, food allergies, inflammatory bowel disease (IBS), Crohn’s disease, ulcerative colitis, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis, eosinophilic colitis, eosinophilic gastritis, eosinophilic cystitis, eosinophilic fasciitis, eosinophilic pustular folliculitis, eosinophilic granulomatosis, eosinophilic polyangiitis, Churg-Strauss syndrome, biliary cancer, brain cancer, breast cancer, colorectal cancer, genitourinary cancer, head and neck cancer, liver cancer, Hodgkin's lymphoma, esophageal cancer, pancreatic cancer, prostate cancer, renal cancer, Kaposi's sarcoma, sinusitis, or chronic urticaria.

[0099] In some embodiments, the light chain variable region comprises an amino acid sequence that is at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or127; and the heavy chain variable region comprises an amino acid sequence that is at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0100] In some embodiments, the light chain variable region comprises an amino acid sequence that is about 90%, about 95%, or about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and the heavy chain variable region comprises an amino acid sequence that is about 90%, about 95%, or about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0101] In some embodiments, the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and / or the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0102] In some embodiments, the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 97, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 98; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 99, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 100; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 101, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 102; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 103, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 104; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 105, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 106; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 107, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 108; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 109, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 110; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 111, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 112; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 113, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 114; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 115, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 116; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 117, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 118; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 119, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 120; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 121, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 122; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 123, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 124; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 125, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 126; or the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 127, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 128.

[0103] In some embodiments, the antibodies or antigen binding fragments thereof comprise a light chain comprising an amino acid sequence that is at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence that is at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0104] In some embodiments, the antibodies or antigen binding fragments thereof comprise a light chain comprising an amino acid sequence that is about 90%, about 95%, or about 99% identical to SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence that is about 90%, about 95%, or about 99% identical to SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201,202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0105] In some embodiments, the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0106] In some embodiments, the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 129, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 130; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 131, and 41 the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 132; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 133, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 134; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 135, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 136; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 137, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 138; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 139, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 140; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 142; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 143, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 144; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 145, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 146; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 148; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 149, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 150; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 151, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 152; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 154; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 155, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 156; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 157, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 158; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 159, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 160; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 182; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 183; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 184; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 185; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 186; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 187; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 188; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 189; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 190; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 191; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 192; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 193; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 194; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 195; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 196; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 197; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 198; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 199; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 200; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 201; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 202; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 203; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 204; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 205; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 206; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 207; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 208; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 209; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 210; or the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 211.

[0107] In some embodiments, the antibodies or antigen binding fragments thereof are monoclonal antibodies.

[0108] In some embodiments, the antibodies or antigen binding fragments thereof are human antibodies.

[0109] In some embodiments, the antibodies or antigen binding fragments thereof are bispecific antibodies.

[0110] In some embodiments, the antigen binding fragment thereof is selected from the group consisting of Fab, Fab’, F(ab’)2, Fd, Fv, scFv, a single-chain antibody, a minibody, and a diabody.

[0111] In some embodiments, the antigen binding fragment thereof is an scFv.

[0112] In some aspects, described herein are antibodies or antigen binding fragments thereof comprising: i) a light chain variable region comprising SEQ ID NO: 1 (LCDR1), SEQ ID NO: 2 (LCDR2), and SEQ ID NO: 3 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 4 (HCDR1), SEQ ID NO: 5 (HCDR2), and SEQ ID NO: 6 (HCDR3); ii) a light chain variable region comprising SEQ ID NO: 7 (LCDR1), SEQ ID NO: 8 (LCDR2), and SEQ ID NO: 9 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 10 (HCDR1), SEQ ID NO: 11 (HCDR2), and SEQ ID NO: 12 (HCDR3); iii) a light chain variable region comprising SEQ ID NO: 13 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 15 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 16 (HCDR1), SEQ ID NO: 17 (HCDR2), and SEQ ID NO: 18 (HCDR3); iv) a light chain variable region comprising SEQ ID NO: 19 (LCDR1), SEQ ID NO: 20 (LCDR2), and SEQ ID NO: 21 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 22 (HCDR1), SEQ ID NO: 23 (HCDR2), and SEQ ID NO: 24 (HCDR3); v) a light chain variable region comprising SEQ ID NO: 25 (LCDR1), SEQ ID NO: 26 (LCDR2), and SEQ ID NO: 27 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3); vi) a light chain variable region comprising SEQ ID NO: 31 (LCDR1), SEQ ID NO: 32 (LCDR2), and SEQ ID NO: 33 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 34 (HCDR1), SEQ ID NO: 35 (HCDR2), and SEQ ID NO: 36 (HCDR3); vii) a light chain variable region comprising SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2), and SEQ ID NO: 39 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 40 (HCDR1), SEQ ID NO: 41 (HCDR2), and SEQ ID NO: 42 (HCDR3); viii) a light chain variable region comprising SEQ ID NO: 43 (LCDR1), SEQ ID NO: 44 (LCDR2), and SEQ ID NO: 45 (LCDR3). and a heavy chain variable region comprising SEQ ID NO: 46 (HCDR1), SEQ ID NO: 47 (HCDR2), and SEQ ID NO: 48 (HCDR3); ix) a light chain variable region comprising SEQ ID NO: 49 (LCDR1), SEQ ID NO: 50 (LCDR2), and SEQ ID NO: 51 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 52 (HCDR1), SEQ ID NO: 53 (HCDR2), and SEQ ID NO: 54 (HCDR3); x) a light chain variable region comprising SEQ ID NO: 55 (LCDR1), SEQ ID NO: 56 (LCDR2), and SEQ ID NO: 57 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 58 (HCDR1), SEQ ID NO: 59 (HCDR2), and SEQ ID NO: 60 (HCDR3); xi) a light chain variable region comprising SEQ ID NO: 61 (LCDR1), SEQ ID NO: 62 (LCDR2), and SEQ ID NO: 63 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 64 (HCDR1), SEQ ID NO: 65 (HCDR2), and SEQ ID NO: 66 (HCDR3); xii) a light chain variable region comprising SEQ ID NO: 67 (LCDR1), SEQ ID NO: 68 (LCDR2), and SEQ ID NO: 69 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 70 (HCDR1), SEQ ID NO: 71 (HCDR2), and SEQ ID NO: 72 (HCDR3); xiii) a light chain variable region comprising SEQ ID NO: 73 (LCDR1), SEQ ID NO: 74 (LCDR2), and SEQ ID NO: 75 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 76 (HCDR1), SEQ ID NO: 77 (HCDR2), and SEQ ID NO: 78 (HCDR3); xiv) a light chain variable region comprising SEQ ID NO: 79 (LCDR1), SEQ ID NO: 80 (LCDR2), and SEQ ID NO: 81 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 82 (HCDR1), SEQ ID NO: 83 (HCDR2), and SEQ ID NO: 84 (HCDR3); xv) a light chain variable region comprising SEQ ID NO: 85 (LCDR1), SEQ ID NO: 86 (LCDR2), and SEQ ID NO: 87 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 88 (HCDR1), SEQ ID NO: 89 (HCDR2), and SEQ ID NO: 90 (HCDR3); or xvi) a light chain variable region comprising SEQ ID NO: 91 (LCDR1), SEQ ID NO: 92 (LCDR2), and SEQ ID NO: 93 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 94 (HCDR1), SEQ ID NO: 95 (HCDR2), and SEQ ID NO: 96 (HCDR3).

[0113] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 comprise a light chain variable region comprising an amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and / or a heavy chain variable region comprising an amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0114] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 comprise a light chain variable region comprising an amino acid sequence that is about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and / or a heavy chain variable region comprising an amino acid sequence that is about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0115] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 comprise a light chain variable region comprising an amino acid sequence as set forth in SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and / or a heavy chain variable region comprising an amino acid sequence as set forth in SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0116] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 comprise: i) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 97, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 98; ii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 99, and a heavy chain variable region comprising an amino acid 46 sequence as set forth in in SEQ ID NO: 100: iii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 101, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 102; vi) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 103, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 104; v) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 105, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 106; vi) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 107, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 108; vii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 109, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 110; vii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 111, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 112; ix) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 113, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 114; x) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 115, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 116; xi) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 117, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 118: xii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 119, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 120; xiii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 121, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 122; xiv) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 123, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 124; xv) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 125, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 126; orxvi) a light chain variable region comprising an amino add sequence as set forth in in SEQ ID NO: 127, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 128.

[0117] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 comprise a light chain comprising an amino acid sequence that is at least about 90%, at ieast about 95%, at ieast about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% Identical to SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0118] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 comprise a light chain comprising an amino acid sequence that is about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence that is about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0119] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 comprises a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or211.

[0120] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 comprise: I) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 129, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 130; ii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 131, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 132; iii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 133, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 134; iv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 135, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 136; v) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 137, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 138; vi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 139, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 140; vii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 142; viii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 143, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 144; ix) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 145, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 146; x) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 148; xi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 149, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 150; xii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 151, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 152; xiii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 154; xiv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 155, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 156; xv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 157, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 158; xvi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 159, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 160; xvii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 182; xviii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 183; xix) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 184; xx) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 185; xxi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 186; xxii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 187; xxiii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 188; xxiv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 189; xxv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 190; xxvi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 191; xxvii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 192; xxviii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 193; xxix) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 194; xxx) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 195; xxxi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 196; xxxii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 197; xxxiii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 198; xxxiv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 199; xxxv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 200; xxxvi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 201; xxxvii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 202; xxxviii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 203; xxxix) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 204; xl) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 205; xli) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 206; xlii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 207; xliii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 208; xliv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 209; xlv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 210; orxlvi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 211.

[0121] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 are monoclonal antibodies.

[0122] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 are human antibodies.

[0123] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 are bispecific antibodies.

[0124] In some embodiments, the antigen binding fragment thereof is selected from the group consisting of: Fab, Fab’, F(ab’)2, Fd, Fv, scFv, a single-chain antibody, a minibody, and a diabody.

[0125] in some embodiments, the antigen binding fragments thereof is an scFv.

[0126] In some aspects, provided herein are antibodies or antigen binding fragments thereof that bind IL-13 used as a medicament.

[0127] in some aspects, provided herein is a pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind IL-13 and a pharmaceutically acceptable carrier.

[0128] in some aspects, provided herein is a nucleic acid composition comprising one or more nucleic acids encoding antibodies or antigen binding fragments thereof that bind IL-13.

[0129] In some aspects, provided herein is an expression vector composition comprising one or more expression vectors comprising a nucleic acid composition as provided herein.

[0130] In some aspects, provided herein is a host cell comprising a nucleic acid composition or an expression vector composition as provided herein.

[0131] In some aspects, provided herein is a method for making anti-IL-13 antibodies or antigen binding fragments thereof comprising culturing the host cell as described herein under conditions where the anti-IL-13 antibodies or antigen binding fragments thereof are expressed and recovering the anti-i L-13 antibodies or binding fragments thereof.

[0132] in some aspects, also provided herein are antibodies or antigen binding fragments thereof that bind IL-13 comprising: a1) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 1 (LCDR1), SEQ ID NO: 2 (LCDR2), and SEQ ID NO: 3 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 4 (HCDR1), SEQ ID NO: 5 (HCDR2), and SEQ ID NO: 6 (HCDR3); a2) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 7 (LCDR1), SEQ ID NO: 8 (LCDR2), and SEQ ID NO: 9 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 10 (HCDR1), SEQ ID NO: 11 (HCDR2), and SEQ ID NO: 12 (HCDR3); a3) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 13 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 15 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 16 (HCDR1), SEQ ID NO: 17 (HCDR2), and SEQ ID NO: 18 (HCDR3); a4) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 19 (LCDR1), SEQ ID NO: 20 (LCDR2), and SEQ ID NO: 21 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 22 (HCDR1), SEQ ID NO: 23 (HCDR2), and SEQ ID NO: 24 (HCDR3); a5) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 25 (LCDR1), SEQ ID NO: 26 (LCDR2), and SEQ ID NO: 27 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3); a6) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 31 (LCDR1), SEQ ID NO: 32 (LCDR2), and SEQ ID NO: 33 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 34 (HCDR1), SEQ ID NO: 35 (HCDR2), and SEQ ID NO: 36 (HCDR3); a7) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2), and SEQ ID NO: 39 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 40 (HCDR1), SEQ ID NO: 41 (HCDR2), and SEQ ID NO: 42 (HCDR3); a8) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 43 (LCDR1), SEQ ID NO: 44 (LCDR2), and SEQ ID NO: 45 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 46 (HCDR1), SEQ ID NO: 47 (HCDR2), and SEQ ID NO: 48 (HCDR3); a9) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 49 (LCDR1), SEQ ID NO: 50 (LCDR2), and SEQ ID NO: 51 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 52 (HCDR1), SEQ ID NO: 53 (HCDR2), and SEQ ID NO: 54 (HCDR3); a10) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 55 (LCDR1), SEQ ID NO: 56 (LCDR2), and SEQ ID NO: 57 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 58 (HCDR1), SEQ ID NO: 59 (HCDR2), and SEQ ID NO: 60 (HCDR3); a11) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 61 (LCDR1), SEQ ID NO: 62 (LCDR2), and SEQ ID NO: 63 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 64 (HCDR1), SEQ ID NO: 65 (HCDR2), and SEQ ID NO: 66 (HCDR3); a12) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 67 (LCDR1), SEQ ID NO: 68 (LCDR2), and SEQ ID NO: 69 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 70 (HCDR1), SEQ ID NO: 71 (HCDR2), and SEQ ID NO: 72 (HCDR3); a13) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 73 (LCDR1), SEQ ID NO: 74 (LCDR2), and SEQ ID NO: 75 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 76 (HCDR1), SEQ ID NO: 77 (HCDR2), and SEQ ID NO: 78 (HCDR3); a14) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 79 (LCDR1), SEQ ID NO: 80 (LCDR2), and SEQ ID NO: 81 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 82 (HCDR1), SEQ ID NO: 83 (HCDR2), and SEQ ID NO: 84 (HCDR3); a15) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 85 (LCDR1), SEQ ID NO: 86 (LCDR2), and SEQ ID NO: 87 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 88 (HCDR1), SEQ ID NO: 89 (HCDR2), and SEQ ID NO: 90 (HCDR3); or a16) light chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 91 (LCDR1), SEQ ID NO: 92 (LCDR2), and SEQ ID NO: 93 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 94 (HCDR1), SEQ ID NO: 95 (HCDR2), and SEQ ID NO: 96 (HCDR3); or b1) a light chain variable region comprising an amino acid sequence at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and b2) a heavy chain variable region comprising an amino acid sequence at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128, wherein the LCDR1 does not include SEQ ID NO: 162 (RASKSVDSYGNSFMH).

[0133] In some aspects, also provided herein are antibodies or antigen binding fragments thereof that bind IL-13 comprising: a1) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 1 (LCDR1), SEQ ID NO: 2 (LCDR2), and SEQ ID NO: 3 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 4 (HCDR1), SEQ ID NO: 5 (HCDR2), and SEQ ID NO: 6 (HCDR3); a2) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 7 (LCDR1), SEQ ID NO: 8 (LCDR2), and SEQ ID NO: 9 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 10 (HCDR1), SEQ ID NO: 11 (HCDR2), and SEQ ID NO: 12 (HCDR3); a3) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 13 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 15 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 16 (HCDR1), SEQ ID NO: 17 (HCDR2), and SEQ ID NO: 18 (HCDR3); a4) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 19 (LCDR1), SEQ ID NO: 20 (LCDR2), and SEQ ID NO: 21 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 22 (HCDR1), SEQ ID NO: 23 (HCDR2), and SEQ ID NO: 24 (HCDR3); a5) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 25 (LCDR1), SEQ ID NO: 26 (LCDR2), and SEQ ID NO: 27 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3); a6) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 31 (LCDR1), SEQ ID NO: 32 (LCDR2), and SEQ ID NO: 33 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 34 (HCDR1), SEQ ID NO: 35 (HCDR2), and SEQ ID NO: 36 (HCDR3); a7) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2), and SEQ ID NO: 39 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 40 (HCDR1), SEQ ID NO: 41 (HCDR2), and SEQ ID NO: 42 (HCDR3); a8) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 43 (LCDR1), SEQ ID NO: 44 (LCDR2), and SEQ ID NO: 45 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 46 (HCDR1), SEQ ID NO: 47 (HCDR2), and SEQ ID NO: 48 (HCDR3); a9) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 49 (LCDR1), SEQ ID NO: 50 (LCDR2), and SEQ ID NO: 51 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 52 (HCDR1), SEQ ID NO: 53 (HCDR2), and SEQ ID NO: 54 (HCDR3); a10) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 55 (LCDR1), SEQ ID NO: 56 (LCDR2), and SEQ ID NO: 57 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 58 (HCDR1), SEQ ID NO: 59 (HCDR2), and SEQ ID NO: 60 (HCDR3); a11) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 61 (LCDR1), SEQ ID NO: 62 (LCDR2), and SEQ ID NO: 63 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 64 (HCDR1), SEQ ID NO: 65 (HCDR2), and SEQ ID NO: 66 (HCDR3); a12) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 67 (LCDR1), SEQ ID NO: 68 (LCDR2), and SEQ ID NO: 69 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 70 (HCDR1), SEQ ID NO: 71 (HCDR2), and SEQ ID NO: 72 (HCDR3); a13) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 73 (LCDR1), SEQ ID NO: 74 (LCDR2), and SEQ ID NO: 75 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 76 (HCDR1), SEQ ID NO: 77 (HCDR2), and SEQ ID NO: 78 (HCDR3); a14) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 79 (LCDR1), SEQ ID NO: 80 (LCDR2), and SEQ ID NO: 81 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 82 (HCDR1), SEQ ID NO: 83 (HCDR2), and SEQ ID NO: 84 (HCDR3); a15) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 85 (LCDR1), SEQ ID NO: 86 (LCDR2), and SEQ ID NO: 87 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 88 (HCDR1), SEQ ID NO: 89 (HCDR2), and SEQ ID NO: 90 (HCDR3); or a16) light chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 91 (LCDR1), SEQ ID NO: 92 (LCDR2), and SEQ ID NO: 93 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 94 (HCDR1), SEQ ID NO: 95 (HCDR2), and SEQ ID NO: 96 (HCDR3); or b1) a light chain variable region comprising an amino acid sequence about 90%, about 95%, or about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and b2) a heavy chain variable region comprising an amino acid sequence about 90%, about 95%, or about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128, wherein the LCDR1 does not include SEQ ID NO: 162 (RASKSVDSYGNSFMH).

[0134] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 comprise a LCDR1 comprising a serine (S) at amino acid position 27D and an arginine (R) at amino acid position 30; a LCDR1 comprising a tyrosine (Y) at amino acid position 27D and a histidine (H) at amino acid position 30; a LCDR1 comprising a tyrosine (Y) at amino acid position 27D and an asparagine (N) at amino acid position 30; or a LCDR1 comprises a serine (S) at amino acid position 27D and a tyrosine (Y) at amino acid position 32, wherein the amino acid positions are based on Kabat numbering.

[0135] In some aspects, also provided herein are antibodies or antigen binding fragments thereof that bind IL-13 comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region is at least about 95%, at least about 96%, at least about 97%, at 56 least about 98%, or at least about 99% identical to SEQ ID NO: 97, 99, 101, and 103; wherein the heavy chain variable region is at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 98, 100, 102, and 104, provided that when serine (S) is present at amino acid position 27D then arginine (R) is present at amino acid position 30 or tyrosine (Y) is present at amino acid position 32, and when asparagine (N) is present at amino acid position 30 then tyrosine (Y) is present at amino acid position 27D, and wherein the amino acid positions are based on Kabat numbering.

[0136] In some aspects, also provided herein are antibodies or antigen binding fragments thereof that bind IL-13 comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region is about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 97, 99, 101, and 103; wherein the heavy chain variable region is about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 98, 100, 102, and 104, provided that when serine (S) is present at amino acid position 27D then arginine (R) is present at amino acid position 30 or tyrosine (Y) is present at amino acid position 32, and when asparagine (N) is present at amino acid position 30 then tyrosine (Y) is present at amino acid position 27D, and wherein the amino acid positions are based on Kabat numbering.

[0137] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 are monoclonal antibodies.

[0138] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 are human antibodies.

[0139] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 are bispecific antibodies.

[0140] In some embodiments, the antigen binding fragment thereof is selected from the group consisting of: Fab, Fab’, F(ab')2, Fd, Fv, scFv, a single-chain antibody, a minibody, and a diabody.

[0141] In some embodiments, the antigen binding fragment thereof is an scFv.

[0142] In some aspects, provided herein are antibodies or antigen binding fragments thereof that bind IL-13 used as a medicament.

[0143] In some aspects, provided herein is a pharmaceutical composition comprising antibodies or an antigen binding fragments thereof and a pharmaceutically acceptable carrier.

[0144] in some aspects, provided herein is a nucleic acid composition comprising one or more nucleic acids encoding antibodies or antigen binding fragments thereof that bind IL-13.

[0145] in some aspects, provided herein is an expression vector composition comprising one or more expression vectors comprising a nucleic acid composition as provided herein.

[0146] In some aspects, provided herein is a host cell comprising a nucleic acid composition or an expression vector composition as provided herein.

[0147] In some aspects, provided herein is a method for making anti-IL-13 antibodies or antigen binding fragments thereof comprising culturing the host cell as described herein under conditions where the anti-IL-13 antibodies or antigen binding fragments thereof are expressed and recovering the anti-IL-13 antibodies or binding fragments thereof.

[0148] In some aspects, described herein is a method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective dose of antibodies or antigen binding fragments thereof that bind IL-13, wherein the antibodies or antigen binding fragments thereof that bind IL-13 comprise: i) a light chain variable region comprising SEQ ID NO: 1 (LCDR1), SEQ ID NO: 2 (LCDR2), and SEQ ID NO: 3 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 4 (HCDR1), SEQ ID NO: 5 (HCDR2), and SEQ ID NO: 6 (HCDR3): ii) a light chain variable region comprising SEQ ID NO: 7 (LCDR1), SEQ ID NO: 8 (LCDR2), and SEQ ID NO: 9 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 10 (HCDR1), SEQ ID NO: 11 (HCDR2), and SEQ ID NO: 12 (HCDR3); iii) a light chain variable region comprising SEQ ID NO: 13 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 15 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 16 (HCDR1), SEQ ID NO: 17 (HCDR2), and SEQ ID NO: 18 (HCDR3); iv) a light chain variable region comprising SEQ ID NO: 19 (LCDR1), SEQ ID NO: 20 (LCDR2), and SEQ ID NO: 21 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 22 (HCDR1), SEQ ID NO: 23 (HCDR2), and SEQ ID NO: 24 (HCDR3); v) a light chain variable region comprising SEQ ID NO: 25 (LCDR1), SEQ ID NO: 26 (LCDR2), and SEQ ID NO: 27 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3); vi) a light chain variable region comprising SEQ ID NO: 31 (LCDR1), SEQ ID NO: 32 (LCDR2), and SEQ ID NO: 33 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 34 (HCDR1), SEQ ID NO: 35 (HCDR2), and SEQ ID NO: 36 (HCDR3); vti) a light chain variable region comprising SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2), and SEQ ID NO: 39 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 40 (HCDR1), SEQ ID NO: 41 (HCDR2), and SEQ ID NO: 42 (HCDR3); viii) a light chain variable region comprising SEQ ID NO: 43 (LCDR1), SEQ ID NO: 44 (LCDR2), and SEQ ID NO: 45 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 46 (HCDR1), SEQ ID NO: 47 (HCDR2), and SEQ ID NO: 48 (HCDR3); ix) a light chain variable region comprising SEQ ID NO: 49 (LCDR1), SEQ ID NO: 50 (LCDR2), and SEQ ID NO: 51 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 52 (HCDR1), SEQ ID NO: 53 (HCDR2), and SEQ ID NO: 54 (HCDR3); x) a light chain variable region comprising SEQ ID NO: 55 (LCDR1), SEQ ID NO: 56 (LCDR2), and SEQ ID NO: 57 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 58 (HCDR1), SEQ ID NO: 59 (HCDR2), and SEQ ID NO: 60 (HCDR3); xi) a light chain variable region comprising SEQ ID NO: 61 (LCDR1), SEQ ID NO: 62 (LCDR2), and SEQ ID NO: 63 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 64 (HCDR1), SEQ ID NO: 65 (HCDR2), and SEQ ID NO: 66 (HCDR3); xii) a light chain variable region comprising SEQ ID NO: 67 (LCDR1), SEQ ID NO: 68 (LCDR2), and SEQ ID NO: 69 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 70 (HCDR1), SEQ ID NO: 71 (HCDR2), and SEQ ID NO: 72 (HCDR3); xiii) a light chain variable region comprising SEQ ID NO: 73 (LCDR1), SEQ ID NO: 74 (LCDR2), and SEQ ID NO: 75 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 76 (HCDR1), SEQ ID NO: 77 (HCDR2), and SEQ ID NO: 78 (HCDR3); xiv) a light chain variable region comprising SEQ ID NO: 79 (LCDR1), SEQ ID NO: 80 (LCDR2), and SEQ ID NO: 81 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 82 (HCDR1), SEQ ID NO: 83 (HCDR2), and SEQ ID NO: 84 (HCDR3); xv) a light chain variable region comprising SEQ ID NO: 85 (LCDR1), SEQ ID NO: 86 (LCDR2), and SEQ ID NO: 87 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 88 (HCDR1), SEQ ID NO: 89 (HCDR2), and SEQ ID NO: 90 (HCDR3); or xvi) a light chain variable region comprising SEQ ID NO: 91 (LCDR1), SEQ ID NO: 92 (LCDR2), and SEQ ID NO: 93 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 94 (HCDR1), SEQ ID NO: 95 (HCDR2), and SEQ ID NO: 96 (HCDR3).

[0149] In some embodiments, the disease or disorder is selected from the group consisting of: asthma (including, but not limited to, mild asthma, mild to moderate asthma, moderate asthma, moderate to severe asthma, and / or severe asthma), allergic asthma, allergen-induced airway obstruction due to asthma and / or allergic asthma, atopic dermatitis (including, but not limited to, mild atopic dermatitis, mild to moderate atopic dermatitis, moderate atopic dermatitis, moderate-to-severe, and / or severe atopic dermatitis), eczema, acute urticaria, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), chronic obstructive airway disease, emphysema, chronic bronchitis, pulmonary fibrosis, systemic sclerosis, scleroderma, cryptogenic fibrosing alveolitis, usual interstitial pneumonitis, idiopathic interstitial pneumonitis, wound, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SS), ulcerative colitis (UC), type 1 diabetes (T1D), sjogren's syndrome (SS), prurigo nodularis, nasal polyposis, recurrent urticaria, aspergillosis, bullous pemphigoid, chronic sinusitis, alopecia areata, hay fever, pemphigus, allergic rhinitis, psoriasis, rosacea, allergic drug reactions, allergic reactions, anaphylaxis, acne, food allergies, inflammatory bowel disease (IBS), Crohn’s disease, ulcerative colitis, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis, eosinophilic colitis, eosinophilic gastritis, eosinophilic cystitis, eosinophilic fasciitis, eosinophilic pustular folliculitis, eosinophilic granulomatosis, eosinophilic polyangiitis, Churg-Strauss syndrome, biliary cancer, brain cancer, breast cancer, colorectal cancer, genitourinary cancer, head and neck cancer, liver cancer, Hodgkin's lymphoma, esophageal cancer, pancreatic cancer, prostate cancer, renal cancer, Kaposi's sarcoma, sinusitis, or chronic urticaria.

[0150] In some embodiments, the light chain variable region comprises an amino acid sequence that is at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or127; and the heavy chain variable region comprises an amino acid sequence that is at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0151] In some embodiments, the light chain variable region comprises an amino acid sequence that is about 90%, about 95%, or about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and the heavy chain variable region comprises an amino acid sequence that is about 90%, about 95%, or about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0152] In some embodiments, the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and / or the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0153] In some embodiments, the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 97, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 98; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 99, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 100; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 101, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 102; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 103, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 104; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 105, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 106; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 107, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 108; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 109, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 110; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 111, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 112; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 113, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 114; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 115, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 116; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 117, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 118; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 119, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 120; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 121, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 122; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 123, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 124; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 125, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 126; or the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 127, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 128.

[0154] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 comprise a light chain comprising an amino acid sequence that is at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence that is at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0155] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 comprise a light chain comprising an amino acid sequence that is about 90%, about 95%, or about 99% identical to SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence that is about 90%, about 95%, or about 99% identical to SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201,202, 203, 204, 205, 206, 207, 208, 209, 210, or211.

[0156] In some embodiments, the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0157] In some embodiments, the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 129, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 130; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 131, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 132; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 133, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 134; the light chain comprises an 62 amino acid sequence as set forth in SEQ ID NO: 135, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 136; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 137, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 138; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 139, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 140; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 142; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 143, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 144; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 145, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 146; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 148; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 149, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 150; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 151, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 152; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 154; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 155, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 156; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 157, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 158; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 159, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 160; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 182; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 183; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 184; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 185; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 186; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 187; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 188; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 189; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 190; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 191; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 192; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 193; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 194; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 195; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 196; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 197; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 198; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 199; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 200; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 201; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 202; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 203; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 204; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 205; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 206; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 207; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 208; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 209; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 210; or the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 211.

[0158] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 are monoclonal antibodies.

[0159] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 are human antibodies.

[0160] In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 are bispecific antibodies.

[0161] In some embodiments, the antigen binding fragment thereof is selected from the group consisting of Fab, Fab’, F(ab’)2, Fd, Fv, scFv, a single-chain antibody, a minibody, and a diabody.

[0162] In some embodiments, the antigen binding fragment thereof is an scFv.

[0163] In some aspects, described herein are antibodies or antigen binding fragments thereof comprising: i) a light chain variable region comprising SEQ ID NO: 1 (LCDR1), SEQ ID NO: 2 (LCDR2), and SEQ ID NO: 3 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 4 (HCDR1). SEQ ID NO: 5 (HCDR2), and SEQ ID NO: 6 (HCDR3); ii) a light chain variable region comprising SEQ ID NO: 7 (LCDR1), SEQ ID NO: 8 (LCDR2), and SEQ ID NO: 9 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 10 (HCDR1), SEQ ID NO: 11 (HCDR2), and SEQ ID NO: 12 (HCDR3); iii) a light chain variable region comprising SEQ ID NO: 13 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 15 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 16 (HCDR1), SEQ ID NO: 17 (HCDR2), and SEQ ID NO: 18 (HCDR3); iv) a light chain variable region comprising SEQ ID NO: 19 (LCDR1), SEQ ID NO: 20 (LCDR2), and SEQ ID NO: 21 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 22 (HCDR1), SEQ ID NO: 23 (HCDR2), and SEQ ID NO: 24 (HCDR3); v) a light chain variable region comprising SEQ ID NO: 25 (LCDR1), SEQ ID NO: 26 (LCDR2), and SEQ ID NO: 27 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3); vi) a light chain variable region comprising SEQ ID NO: 31 (LCDR1), SEQ ID NO: 32 (LCDR2), and SEQ ID NO: 33 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 34 (HCDR1), SEQ ID NO: 35 (HCDR2), and SEQ ID NO: 36 (HCDR3); vii) a light chain variable region comprising SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2), and SEQ ID NO: 39 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 40 (HCDR1), SEQ ID NO: 41 (HCDR2), and SEQ ID NO: 42 (HCDR3); viii) a light chain variable region comprising SEQ ID NO: 43 (LCDR1), SEQ ID NO: 44 (LCDR2), and SEQ ID NO: 45 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 46 (HCDR1), SEQ ID NO: 47 (HCDR2), and SEQ ID NO: 48 (HCDR3); ix) a light chain variable region comprising SEQ ID NO: 49 (LCDR1), SEQ ID NO: 50 (LCDR2), and SEQ ID NO: 51 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 52 (HCDR1), SEQ ID NO: 53 (HCDR2), and SEQ ID NO: 54 (HCDR3); x) a light chain variable region comprising SEQ ID NO: 55 (LCDR1), SEQ ID NO: 56 (LCDR2), and SEQ ID NO: 57 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 58 (HCDR1), SEQ ID NO: 59 (HCDR2), and SEQ ID NO: 60 (HCDR3): xi) a light chain variable region comprising SEQ ID NO: 61 (LCDR1), SEQ ID NO: 62 (LCDR2), and SEQ ID NO: 63 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 64 (HCDR1), SEQ ID NO: 65 (HCDR2), and SEQ ID NO: 66 (HCDR3); xii) a light chain variable region comprising SEQ ID NO: 67 (LCDR1), SEQ ID NO: 68 (LCDR2), and SEQ ID NO: 69 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 70 (HCDR1), SEQ ID NO: 71 (HCDR2), and SEQ ID NO: 72 (HCDR3); xiii) a light chain variable region comprising SEQ ID NO: 73 (LCDR1), SEQ ID NO: 74 (LCDR2), and SEQ ID NO: 75 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 76 (HCDR1), SEQ ID NO: 77 (HCDR2), and SEQ ID NO: 78 (HCDR3); xiv) a light chain variable region comprising SEQ ID NO: 79 (LCDR1), SEQ ID NO: 80 (LCDR2), and SEQ ID NO: 81 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 82 (HCDR1), SEQ ID NO: 83 (HCDR2), and SEQ ID NO: 84 (HCDR3); xv) a light chain variable region comprising SEQ ID NO: 85 (LCDR1), SEQ ID NO: 86 (LCDR2), and SEQ ID NO: 87 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 88 (HCDR1), SEQ ID NO: 89 (HCDR2), and SEQ ID NO: 90 (HCDR3): or xvi) a light chain variable region comprising SEQ ID NO: 91 (LCDR1), SEQ ID NO: 92 (LCDR2), and SEQ ID NO: 93 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 94 (HCDR1), SEQ ID NO: 95 (HCDR2), and SEQ ID NO: 96 (HCDR3).

[0164] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 comprise a light chain variable region comprising an amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and / or a heavy chain variable region comprising an amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0165] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 comprise a light chain variable region comprising an amino acid sequence that is about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and / or a heavy chain variable region comprising an amino acid sequence that is about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0166] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 comprise a light chain variable region comprising an amino acid sequence as set forth in SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and / ora heavy chain variable region comprising an amino acid sequence as set forth in SEQ ID NO: 98, 100. 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0167] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 comprise: I) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 97, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 98; ii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 99, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 100; iii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 101, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 102; vi) a light chain variable region 67 comprising an amino acid sequence as set forth in in SEQ ID NO: 103, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 104; v) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 105, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 106; vi) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 107, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 108; vii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 109, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 110; vii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 111, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 112; ix) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 113, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 114; x) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 115, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 116; xi) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 117, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 118; xii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 119, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 120; xiii) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 121, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 122; xiv) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 123, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 124; xv) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 125, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 126; orxvi) a light chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 127, and a heavy chain variable region comprising an amino acid sequence as set forth in in SEQ ID NO: 128.

[0168] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 comprise a light chain comprising an amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0169] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 comprise a light chain comprising an amino acid sequence that is about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence that is about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0170] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 comprises a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or211.

[0171] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 comprise: i) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 129, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 130; ii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 131, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 132; iii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 133, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 134; iv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 135, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 136; v) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 137, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 138; vi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 139, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 140; vii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 142; viii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 143, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 144; ix) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 145, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 146; x) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 148; xi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 149, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 150; xii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 151, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 152; xiii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 154; xiv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 155, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 156; xv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 157, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 158; xvi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 159, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 160; xvii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 182; xviii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 183; xix) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 184; xx) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 185; xxi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 186; xxii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 187; xxiii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 188; xxiv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 189; xxv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 190; xxvi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 191; xxvii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 192; xxviii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 193; xxix) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 194; xxx) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 195; xxxi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 196; xxxii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 197; xxxiii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 198; xxxiv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 199; xxxv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 200; xxxvi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 201; xxxvii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 202; xxxviii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 203; xxxix) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 204; xl) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 205; xli) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 206; xlii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 207; xliii) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 208; xliv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 153, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 209; xlv) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 147, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 210; or xlvi) a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 141, and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 211.

[0172] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 are monoclonal antibodies.

[0173] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 are human antibodies.

[0174] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 are bispecific antibodies.

[0175] In some embodiments, the antigen binding fragment thereof is selected from the group consisting of: Fab, Fab’, F(ab’)2, Fd, Fv, scFv, a single-chain antibody, a minibody, and a diabody.

[0176] In some embodiments, the antigen binding fragments thereof is an scFv.

[0177] In some aspects, provided herein are antibodies or antigen binding fragments thereof for binding IL-13 used as a medicament.

[0178] In some aspects, provided herein is a pharmaceutical composition comprising antibodies or antigen binding fragments thereof for binding IL-13 and a pharmaceutically acceptable carrier.

[0179] In some aspects, provided herein is a nucleic acid composition comprising one or more nucleic acids encoding antibodies or antigen binding fragments thereof for binding IL-13.

[0180] In some aspects, provided herein is an expression vector composition comprising one or more expression vectors comprising a nucleic acid composition as provided herein.

[0181] In some aspects, provided herein is a host ceil comprising a nucleic acid composition or an expression vector composition as provided herein.

[0182] in some aspects, provided herein is a method for making anti-IL-13 antibodies or antigen binding fragments thereof comprising culturing the host cell as described herein under conditions where the anti-IL-13 antibodies or antigen binding fragments thereof are expressed and recovering the anti-IL-13 antibodies or binding fragments thereof.

[0183] In some aspects, also provided herein are antibodies or antigen binding fragments thereof for binding IL-13 comprising: a1) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 1 (LCDR1), SEQ ID NO: 2 (LCDR2), and SEQ ID NO: 3 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 4 (HCDR1), SEQ ID NO: 5 (HCDR2), and SEQ ID NO: 6 (HCDR3); a2) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 7 (LCDR1), SEQ ID NO: 8 (LCDR2), and SEQ ID NO: 9 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 10 (HCDR1), SEQ ID NO: 11 (HCDR2), and SEQ ID NO: 12 (HCDR3); a3) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 13 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 15 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 16 (HCDR1), SEQ ID NO: 17 (HCDR2), and SEQ ID NO: 18 (HCDR3); a4) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 19 (LCDR1), SEQ ID NO: 20 (LCDR2), and SEQ ID NO: 21 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 22 (HCDR1), SEQ ID NO: 23 (HCDR2), and SEQ ID NO: 24 (HCDR3); a5) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 25 (LCDR1), SEQ ID NO: 26 (LCDR2), and SEQ ID NO: 27 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3); a6) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 31 (LCDR1), SEQ ID NO: 32 (LCDR2), and SEQ ID NO: 33 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 34 (HCDR1), SEQ ID NO: 35 (HCDR2), and SEQ ID NO: 36 (HCDR3); a7) light chain CDRs comprising amino acid 73 sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2), and SEQ ID NO: 39 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 40 (HCDR1), SEQ ID NO: 41 (HCDR2), and SEQ ID NO: 42 (HCDR3); a8) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 43 (LCDR1), SEQ ID NO: 44 (LCDR2), and SEQ ID NO: 45 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 46 (HCDR1), SEQ ID NO: 47 (HCDR2), and SEQ ID NO: 48 (HCDR3); a9) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 49 (LCDR1), SEQ ID NO: 50 (LCDR2), and SEQ ID NO: 51 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 52 (HCDR1), SEQ ID NO: 53 (HCDR2), and SEQ ID NO: 54 (HCDR3); a10) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 55 (LCDR1), SEQ ID NO: 56 (LCDR2), and SEQ ID NO: 57 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 58 (HCDR1), SEQ ID NO: 59 (HCDR2), and SEQ ID NO: 60 (HCDR3); a11) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 61 (LCDR1), SEQ ID NO: 62 (LCDR2), and SEQ ID NO: 63 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 64 (HCDR1), SEQ ID NO: 65 (HCDR2), and SEQ ID NO: 66 (HCDR3); a12) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 67 (LCDR1), SEQ ID NO: 68 (LCDR2), and SEQ ID NO: 69 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 70 (HCDR1), SEQ ID NO: 71 (HCDR2), and SEQ ID NO: 72 (HCDR3); a13) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 73 (LCDR1), SEQ ID NO: 74 (LCDR2), and SEQ ID NO: 75 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 76 (HCDR1), SEQ ID NO: 77 (HCDR2), and SEQ ID NO: 78 (HCDR3); a14) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 79 (LCDR1), SEQ ID NO: 80 (LCDR2), and SEQ ID NO: 81 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 82 (HCDR1), SEQ ID NO: 83 (HCDR2), and SEQ ID NO: 84 (HCDR3); a15) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 85 (LCDR1), SEQ ID NO: 86 (LCDR2), and SEQ ID NO: 87 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 88 (HCDR1), SEQ ID NO: 89 (HCDR2), and SEQ ID NO: 90 (HCDR3); or a16) light chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 91 (LCDR1), SEQ ID NO: 92 (LCDR2), and SEQ ID NO: 93 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 94 (HCDR1), SEQ ID NO: 95 (HCDR2), and SEQ ID NO: 96 (HCDR3); or b1) a light chain variable region comprising an amino acid sequence at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and b2) a heavy chain variable region comprising an amino acid sequence at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128, wherein the LCDR1 does not include SEQ ID NO: 162 (RASKSVDSYGNSFMH).

[0184] in some aspects, also provided herein are antibodies or antigen binding fragments thereof for binding IL-13 comprising: a1) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 1 (LCDR1), SEQ ID NO: 2 (LCDR2), and SEQ ID NO: 3 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 4 (HCDR1), SEQ ID NO: 5 (HCDR2), and SEQ ID NO: 6 (HCDR3); a2) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 7 (LCDR1), SEQ ID NO: 8 (LCDR2), and SEQ ID NO: 9 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 10 (HCDR1), SEQ ID NO: 11 (HCDR2), and SEQ ID NO: 12 (HCDR3); a3) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 13 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 15 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 16 (HCDR1), SEQ ID NO: 17 (HCDR2), and SEQ ID NO: 18 (HCDR3); a4) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 19 (LCDR1), SEQ ID NO: 20 (LCDR2), and SEQ ID NO: 21 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 22 (HCDR1), SEQ ID NO: 23 (HCDR2), and SEQ ID NO: 24 (HCDR3); a5) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 25 (LCDR1), SEQ ID NO: 26 (LCDR2), and SEQ ID NO: 27 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3); a6) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 31 (LCDR1), SEQ ID NO: 32 (LCDR2), and SEQ ID NO: 33 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 34 (HCDR1), SEQ ID NO: 35 (HCDR2), and SEQ ID NO: 36 (HCDR3); a7) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2), and SEQ ID NO: 39 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 40 (HCDR1), SEQ ID NO: 41 (HCDR2), and SEQ ID NO: 42 (HCDR3); a8) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 43 (LCDR1), SEQ ID NO: 44 (LCDR2), and SEQ ID NO: 45 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 46 (HCDR1), SEQ ID NO: 47 (HCDR2), and SEQ ID NO: 48 (HCDR3); a9) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 49 (LCDR1), SEQ ID NO: 50 (LCDR2), and SEQ ID NO: 51 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 52 (HCDR1), SEQ ID NO: 53 (HCDR2), and SEQ ID NO: 54 (HCDR3); a10) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 55 (LCDR1), SEQ ID NO: 56 (LCDR2), and SEQ ID NO: 57 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 58 (HCDR1), SEQ ID NO: 59 (HCDR2), and SEQ ID NO: 60 (HCDR3); a11) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 61 (LCDR1), SEQ ID NO: 62 (LCDR2), and SEQ ID NO: 63 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 64 (HCDR1), SEQ ID NO: 65 (HCDR2), and SEQ ID NO: 66 (HCDR3); a12) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 67 (LCDR1), SEQ ID NO: 68 (LCDR2), and SEQ ID NO: 69 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 70 (HCDR1), SEQ ID NO: 71 (HCDR2), and SEQ ID NO: 72 (HCDR3); a13) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 73 (LCDR1), SEQ ID NO: 74 (LCDR2), and SEQ ID NO: 75 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 76 (HCDR1), SEQ ID NO: 77 (HCDR2), and SEQ ID NO: 78 (HCDR3); a14) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 79 (LCDR1), SEQ ID NO: 80 (LCDR2), and SEQ ID NO: 81 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 82 (HCDR1), SEQ ID NO: 83 (HCDR2), and SEQ ID NO: 84 (HCDR3); a15) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 85 (LCDR1), SEQ ID NO: 86 (LCDR2), and SEQ ID NO: 87 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 88 (HCDR1), SEQ ID NO: 89 (HCDR2), and SEQ ID NO: 90 (HCDR3); or a16) light chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 91 (LCDR1), SEQ ID NO: 92 (LCDR2), and SEQ ID NO: 93 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 94 (HCDR1), SEQ ID NO: 95 (HCDR2), and SEQ ID NO: 96 (HCDR3); or b1) a light chain variable region comprising an amino acid sequence about 90%, about 95%, or about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and b2) a heavy chain variable region comprising an amino acid sequence about 90%, about 95%, or about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128, wherein the LCDR1 does not include SEQ ID NO: 162 (RASKSVDSYGNSFMH).

[0185] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 comprise a LCDR1 comprising a serine (S) at amino acid position 27D and an arginine (R) at amino acid position 30; a LCDR1 comprising a tyrosine (Y) at amino acid position 27D and a histidine (H) at amino acid position 30; a LCDR1 comprising a tyrosine (Y) at amino acid position 27D and an asparagine (N) at amino acid position 30; or a LCDR1 comprises a serine (S) at amino acid position 27D and a tyrosine (Y) at amino acid position 32, wherein the amino acid positions are based on Kabat numbering.

[0186] In some aspects, also provided herein are antibodies or antigen binding fragments thereof for binding IL-13 comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region is at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 97, 99, 101, and 103; wherein the heavy chain variable region is at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 98, 100, 102, and 104, 77 provided that when serine (S) is present at amino acid position 27D then arginine (R) is present at amino acid position 30 or tyrosine (Y) is present at amino acid position 32, and when asparagine (N) is present at amino acid position 30 then tyrosine (Y) is present at amino acid position 27D, and wherein the amino acid positions are based on Kabat numbering.

[0187] In some aspects, also provided herein are antibodies or antigen binding fragments thereof for binding IL-13 comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region is about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 97, 99, 101, and 103; wherein the heavy chain variable region is about 95%, about 96%, about 97%, about 98%, or about 99% identical to SEQ ID NO: 98, 100, 102, and 104, provided that when serine (S) is present at amino acid position 27D then arginine (R) is present at amino acid position 30 or tyrosine (Y) is present at amino acid position 32, and when asparagine (N) is present at amino acid position 30 then tyrosine (Y) is present at amino acid position 27D, and wherein the amino acid positions are based on Kabat numbering.

[0188] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 are monoclonal antibodies.

[0189] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 are human antibodies.

[0190] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 are bispecific antibodies.

[0191] In some embodiments, the antigen binding fragment thereof is selected from the group consisting of: Fab, Fab’, F(ab’)2, Fd, Fv, scFv, a single-chain antibody, a minibody, and a diabody.

[0192] In some embodiments, the antigen binding fragment thereof is an scFv.

[0193] In some aspects, provided herein are antibodies or antigen binding fragments thereof for binding IL-13 used as a medicament.

[0194] In some aspects, provided herein is a pharmaceutical composition comprising antibodies or an antigen binding fragments thereof and a pharmaceutically acceptable carrier.

[0195] In some aspects, provided herein is a nucleic acid composition comprising one or more nucleic acids encoding antibodies or antigen binding fragments thereof for binding IL-13.

[0196] In some aspects, provided herein is an expression vector composition comprising one or more expression vectors comprising a nucleic acid composition as provided herein.

[0197] In some aspects, provided herein is a host cell comprising a nucleic acid composition or an expression vector composition as provided herein.

[0198] In some aspects, provided herein is a method for making anti-IL-13 antibodies or antigen binding fragments thereof comprising culturing the host cell as described herein under conditions where the anti-IL-13 antibodies or antigen binding fragments thereof are expressed and recovering the anti-IL-13 antibodies or binding fragments thereof.

[0199] In some aspects, described herein is a method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective dose of antibodies or antigen binding fragments thereof for binding IL-13, wherein the antibodies or antigen binding fragments thereof for binding IL-13 comprise: i) a light chain variable region comprising SEQ ID NO: 1 (LCDR1), SEQ ID NO: 2 (LCDR2), and SEQ ID NO: 3 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 4 (HCDR1), SEQ ID NO: 5 (HCDR2), and SEQ ID NO: 6 (HCDR3); ii) a light chain variable region comprising SEQ ID NO: 7 (LCDR1), SEQ ID NO: 8 (LCDR2), and SEQ ID NO: 9 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 10 (HCDR1), SEQ ID NO: 11 (HCDR2), and SEQ ID NO: 12 (HCDR3); iii) a light chain variable region comprising SEQ ID NO: 13 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 15 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 16 (HCDR1). SEQ ID NO: 17 (HCDR2), and SEQ ID NO: 18 (HCDR3); iv) a light chain variable region comprising SEQ ID NO: 19 (LCDR1), SEQ ID NO: 20 (LCDR2), and SEQ ID NO: 21 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 22 (HCDR1), SEQ ID NO: 23 (HCDR2), and SEQ ID NO: 24 (HCDR3); v) a light chain variable region comprising SEQ ID NO: 25 (LCDR1), SEQ ID NO: 26 (LCDR2), and SEQ ID NO: 27 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3); vi) a light chain variable region comprising SEQ ID NO: 31 (LCDR1), SEQ ID NO: 32 (LCDR2), and SEQ ID NO: 33 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 34 (HCDR1), SEQ ID NO: 35 (HCDR2), and SEQ ID NO: 36 (HCDR3); vii) a light chain variable region comprising SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2), and SEQ ID NO: 79 39 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 40 (HCDR1), SEQ ID NO: 41 (HCDR2), and SEQ ID NO: 42 (HCDR3); viii) a light chain variable region comprising SEQ ID NO: 43 (LCDR1), SEQ ID NO: 44 (LCDR2), and SEQ ID NO: 45 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 46 (HCDR1), SEQ ID NO: 47 (HCDR2), and SEQ ID NO: 48 (HCDR3); ix) a light chain variable region comprising SEQ ID NO: 49 (LCDR1), SEQ ID NO: 50 (LCDR2), and SEQ ID NO: 51 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 52 (HCDR1), SEQ ID NO: 53 (HCDR2), and SEQ ID NO: 54 (HCDR3); x) a light chain variable region comprising SEQ ID NO: 55 (LCDR1), SEQ ID NO: 56 (LCDR2), and SEQ ID NO: 57 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 58 (HCDR1), SEQ ID NO: 59 (HCDR2), and SEQ ID NO: 60 (HCDR3); xi) a light chain variable region comprising SEQ ID NO: 61 (LCDR1), SEQ ID NO: 62 (LCDR2), and SEQ ID NO: 63 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 64 (HCDR1), SEQ ID NO: 65 (HCDR2), and SEQ ID NO: 66 (HCDR3); xii) a light chain variable region comprising SEQ ID NO: 67 (LCDR1), SEQ ID NO: 68 (LCDR2), and SEQ ID NO: 69 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 70 (HCDR1), SEQ ID NO: 71 (HCDR2), and SEQ ID NO: 72 (HCDR3); xiii) a light chain variable region comprising SEQ ID NO: 73 (LCDR1), SEQ ID NO: 74 (LCDR2), and SEQ ID NO: 75 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 76 (HCDR1), SEQ ID NO: 77 (HCDR2), and SEQ ID NO: 78 (HCDR3); xiv) a light chain variable region comprising SEQ ID NO: 79 (LCDR1), SEQ ID NO: 80 (LCDR2), and SEQ ID NO: 81 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 82 (HCDR1), SEQ ID NO: 83 (HCDR2), and SEQ ID NO: 84 (HCDR3); xv) a light chain variable region comprising SEQ ID NO: 85 (LCDR1), SEQ ID NO: 86 (LCDR2), and SEQ ID NO: 87 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 88 (HCDR1), SEQ ID NO: 89 (HCDR2), and SEQ ID NO: 90 (HCDR3); orxvi) a light chain variable region comprising SEQ ID NO: 91 (LCDR1), SEQ ID NO: 92 (LCDR2), and SEQ ID NO: 93 (LCDR3), and a heavy chain variable region comprising SEQ ID NO: 94 (HCDR1), SEQ ID NO: 95 (HCDR2), and SEQ ID NO: 96 (HCDR3).

[0200] In some embodiments, the disease or disorder is selected from the group consisting of: asthma (including, but not limited to, mild asthma, mild to moderate asthma, moderate asthma, moderate to severe asthma, and / or severe asthma), allergic asthma, allergen-induced airway obstruction due to asthma and / or allergic asthma, atopic dermatitis (including, but not limited to, mild atopic dermatitis, mild to moderate atopic dermatitis, moderate atopic dermatitis, moderate-to-severe, and / or severe atopic dermatitis), eczema, acute urticaria, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), chronic obstructive airway disease, emphysema, chronic bronchitis, pulmonary fibrosis, systemic sclerosis, scleroderma, cryptogenic fibrosing alveolitis, usual interstitial pneumonitis, idiopathic interstitial pneumonitis, wound, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SS), ulcerative colitis (UC), type 1 diabetes (T1D), sjogren's syndrome (SS), prurigo nodularis, nasal polyposis, recurrent urticaria, aspergillosis, bullous pemphigoid, chronic sinusitis, alopecia areata, hay fever, pemphigus, allergic rhinitis, psoriasis, rosacea, allergic drug reactions, allergic reactions, anaphylaxis, acne, food allergies, inflammatory bowel disease (IBS), Crohn’s disease, ulcerative colitis, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis, eosinophilic colitis, eosinophilic gastritis, eosinophilic cystitis, eosinophilic fasciitis, eosinophilic pustular folliculitis, eosinophilic granulomatosis, eosinophilic polyangiitis, Churg-Strauss syndrome, biliary cancer, brain cancer, breast cancer, colorectal cancer, genitourinary cancer, head and neck cancer, liver cancer, Hodgkin's lymphoma, esophageal cancer, pancreatic cancer, prostate cancer, renal cancer, Kaposi's sarcoma, sinusitis, or chronic urticaria.

[0201] In some embodiments, the light chain variable region comprises an amino acid sequence that is at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or127; and the heavy chain variable region comprises an amino acid sequence that is at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0202] In some embodiments, the light chain variable region comprises an amino acid sequence that is about 90%, about 95%, or about 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and the heavy chain variable region comprises an amino acid sequence that is about 90%, about 95%, or about 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0203] In some embodiments, the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and / or the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

[0204] In some embodiments, the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 97, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 98; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 99, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 100; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 101, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 102; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 103, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 104; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 105, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 106; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 107, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 108; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 109, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 110; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 111, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 112; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 113, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 114; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 115, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 116; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 117, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 118; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 119, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 120; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 121, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 122; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 123, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 124; the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 125, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 126; or the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 127, and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 128.

[0205] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 comprise a light chain comprising an amino acid sequence that is at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence that is at least about 90%, at least about 95%, or at least about 99% identical to SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0206] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 comprise a light chain comprising an amino acid sequence that is about 90%, about 95%, or about 99% identical to SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence that is about 90%, about 95%, or about 99% identical to SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0207] In some embodiments, the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0208] In some embodiments, the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 129, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 130; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 131, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 132; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 133, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 134; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 135, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 136; the light chain comprises an amino acid sequence 83 as set forth in SEQ ID NO: 137, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 138; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 139, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 140; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 142; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 143, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 144; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 145, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 146; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 148; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 149, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 150; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 151, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 152; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 154; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 155, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 156; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 157, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 158; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 159, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 160; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 182; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 183; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 184; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 185; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 186; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 187; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 188; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 189; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 190; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 191; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 192; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 193; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 194; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 195; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 196; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 197; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 198; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 199; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 200; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 201; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 202; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 203; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 204; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 205; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 206; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 207; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 208; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 209; the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 210; or the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141, and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 211.

[0209] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 are monoclonal antibodies.

[0210] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 are human antibodies.

[0211] In some embodiments, the antibodies or antigen binding fragments thereof for binding IL-13 are bispecific antibodies.

[0212] In some embodiments, the antigen binding fragment thereof is selected from the group consisting of Fab, Fab’, F(ab’)2, Fd, Fv, scFv, a single-chain antibody, a minibody, and a diabody.

[0213] In some embodiments, the antigen binding fragment thereof is an scFv.

[0214] In an aspect, provided herein is a computer-implemented method comprising scoring a polypeptide comprising an amino acid sequence with a computationally binding optimized (CBO) model for a functional property relating to modulating the activity of a target molecule, the CBO model: for each amino acid position of the amino acid sequence of the polypeptide, calculating a plurality of energy scores, the energy scores based on the amino acid at a given position in the amino acid sequence, adding each energy score calculated to an array, generating a normalized sum of the energy scores for each position, and generating a score of the polypeptide by summing each energy score calculated, the score representing the functional property of the polypeptide, the functional property relating to the polypeptide modulating the activity of the target molecule.

[0215] In some embodiments, the computer-implemented method further comprises calculating a logarithm of each energy score calculated; wherein summing each energy score calculated is performed by summing the logarithms of each energy score calculated; wherein the energy scores are further calculated based on having substituted the amino acid at the given position in the amino acid sequence with each of a plurality of different amino acids.

[0216] In some embodiments, the scoring the polypeptide using the CBO model is implementable by the script of Appendix A, and the CBO model is substantially similar to the table of Appendix B.

[0217] In some embodiments, the functional property is at least one of: a binding affinity for an interleukin-13 (IL-13) polypeptide characterized by a Ko of 10 pM or less (optionally, as measured by KinExA); a binding specificity for the IL-13 polypeptide; a neutralizing activity against the IL-13 polypeptide (optionally, a full-length human IL-13); or an inhibitory activity against IL-13-mediated signaling, or a combination of the foregoing.

[0218] In some embodiments, the target molecule is interleukin-13 (IL-13), and the functional property of the relating to the polypeptide modulates the activity of the IL-13.

[0219] In an aspect, provided herein is a system comprising: a processor; and a memory with computer code instructions stored thereon, the processor and the memory, with the computer code instructions, being configured to cause the system to: score a polypeptide comprising an amino acid sequence with a CBO model for a functional property relating to modulating the activity of a target molecule, the CBO model: for each amino acid position of the amino acid sequence of the polypeptide, calculating a plurality of energy scores, the energy scores based on the amino acid at a given position in the amino acid sequence, add each energy score calculated to an array, generate a normalized sum of the energy scores for each position, and generate a score of the amino acid sequence by summing each energy score calculated, the score representing a functional property of the polypeptide, the functional property relating to the polypeptide modulating the activity of the target molecules.

[0220] In some embodiments, the instructions are further configured to cause the system to calculate a logarithm of each energy score calculated; wherein summing each energy score calculated is performed by summing the logarithms of each energy score calculated; wherein the energy scores are further based on having substituted the amino acid at the given position in the amino acid sequence with each of a plurality of different amino acids.

[0221] In some embodiments, scoring the polypeptide using the CBO model is implemented by the script of Appendix A and wherein the CBO model is substantially similar to the table of Appendix B.

[0222] In some embodiments, the functional property is at least one of: a binding affinity for an interleukin-13 (IL-13) polypeptide characterized by a KD of 10 pM or less (optionally, as measured by KinExA); a binding specificity for the IL-13 polypeptide; a neutralizing activity against the IL-13 polypeptide (optionally, a full-length human IL-13); or an inhibitory activity against IL-13-mediated signaling, or a combination of the foregoing.

[0223] In some embodiments, the target molecule is interleukin-13 (IL-13), and the functional property of the relating to the polypeptide modulates the activity of the IL-13.

[0224] In an aspect, provided herein is a polypeptide that specifically binds an interleukin-13 (IL-13): wherein the polypeptide comprises an amino acid sequence that is assigned a score above a predetermined threshold by a computationally binding optimized (CBO) model upon scoring the amino acid sequence of the polypeptide.

[0225] In some embodiments, the polypeptide is scorable by the script of Computer Program Listing Appendix A and wherein the CBO model is calculated by a table substantially similar to that of Computer Program Listing Appendix B and wherein the polypeptide is assigned the score that is calculated using the Computer Program Listing Appendix B; wherein the polypeptide is assigned the score by a script substantially similar to Computer Program Listing Appendix A, the script employing the CBO model substantially similar to the table of Computer Program Listing Appendix B, wherein the polypeptide has a logarithmic score of at least about: -1.7, -1.0, -0.5, 0, 0.5, 1, 1.5, 1.8,2.0, and 3.0.

[0226] In some embodiments, the polypeptide has one or more properties selected from: a binding affinity for an interleukin-13 (IL-13) polypeptide characterized by a Ko of 10 pM or less (optionally, as measured by KinExA); a binding specificity for the IL-13 polypeptide; a neutralizing activity against the IL-13 polypeptide (optionally, a full-length human IL-13); or an inhibitory activity against IL-13-mediated signaling, or a combination of the foregoing.

[0227] In some embodiments, the CBO model outputs a score that is equal to or above a score from the CBO model of one or more of a reference polypeptide that comprises a VL and VH pair selected from: SEQ ID NO: 97 and SEQ ID NO: 98 (AbA); SEQ ID NO: 99 and SEQ ID NO: 100 (AbB); SEQ ID NO: 101 and SEQ ID NO: 102 (AbC); SEQ ID NO: 103 and SEQ ID NO: 104 (AbD); SEQ ID NO: 105 and SEQ ID NO: 106 (AbE); SEQ ID NO: 107 and SEQ ID NO: 108 (AbF); SEQ ID NO: 109 and SEQ ID NO: 110 (AbG); SEQ ID NO: 111 and SEQ ID NO: 112 (AbH); SEQ ID NO: 113 and SEQ ID NO: 114 (Abi); SEQ ID NO: 115 and SEQ ID NO: 116 (AbJ); SEQ ID NO: 117 and SEQ ID NO: 118 (AbK); SEQ ID NO: 119 and SEQ ID NO: 120 (AbL); SEQ ID NO: 121 and SEQ ID NO: 122 (AbM); SEQ ID NO: 123 and SEQ ID NO: 124 (AbN); SEQ ID NO: 125 and SEQ ID NO: 126 (AbO); or SEQ ID NO: 127 and SEQ ID NO: 128 (AbP).

[0228] In some embodiments, the polypeptide does not comprise a heavy chain comprising SEQ ID NO: 179 or 181 and a light chain comprising SEQ ID NO: 178 or 180.

[0229] In an aspect, provided herein is a polypeptide: wherein the polypeptide comprises an amino acid sequence that is assigned a score above a predetermined threshold by a computationally binding optimized (CBO) model upon scoring the amino acid sequence of the polypeptide.

[0230] In an aspect, provided herein is a polypeptide that binds human interleukin-13 (IL-13), wherein the polypeptide is designed by a method comprising: generating a polypeptide sequence with a CBO model; verifying the generated polypeptide sequence using the CBO model by: for each amino acid position of the polypeptide sequence, calculating a plurality of energy scores, the energy scores based on having substituted the amino acid at a given position in the polypeptide sequence with each of a plurality of different amino acids, adding each energy score calculated to an array, generating a normalized sum of the energy scores for each position, calculating a logarithm of each energy score calculated, and generating a score of the polypeptide sequence by summing the logarithms of each energy score calculated, the score representing a functional property of the polypeptide’s ability to bind to human IL-13. BRIEF DESCRIPTION OF THE DRAWINGS

[0231] The foregoing summary, as well as the following detailed description, will be better understood when read in conjunction with the appended figures. For the purpose of illustration, shown in the figures are embodiments. It should be understood, however, that the summary, detailed description, and figures are not limited to the precise arrangements, examples, and instrumentalities shown.

[0232] Figure 1: Figures 1A-F demonstrate anti-IL-13 antibodies neutralizing the signaling of IL-13 through IL-13Ra1 / IL-4Ra expressed on HEK-Blue cells. IL-13Ra1 / IL-4Ra HEK-Blue cells express STAT6 and a STAT6 inducible SEAP reporter that is induced by IL-13 binding to IL-13Ra1. Ref1 is a reference molecule and positive control. Data are analyzed by normalizing response to the lgG1 isotype negative control to obtain percent inhibition. ICS0 values are calculated by fitting a 4-parameter non-linear regression curve using the average of four technical replicates per antibody concentration.

[0233] Figure 2. Figure 2 demonstrates an anti-IL-13 antibody blocking IL-13 and inhibiting pSTAT6 induced SEAP reporter activity in the HEK-Blue IL-4 / IL-13 Assay. Results displayed are expressed in percent inhibition (n=3 technical replicates from one representative biological replicate), as compared to stimulated but unblocked cells (IL-13 alone), as mean + / - SEM.

[0234] Figure 3. Figure 3 demonstrates an anti-IL-13 antibody blocking human IL-13 and prevent it from signaling through the IL-4Ra1 / IL-13Ra1 complex and downstream pSTAT6 signal on human monocytes (n=3 technical replicates from Donor 3). Results displayed are expressed in percent inhibition of pSTAT6 signal, as compared to an isotype control, as mean + / - SEM.

[0235] Figure 4. Figure 4 demonstrates an anti-IL-13 antibody blocking cynomolgus IL-13 and prevent it from signaling through the IL-4Ra1 / IL-13Ra1 complex and downstream pSTAT6 signal on cynomolgus monocytes (n=3 technical replicates from Donor 1). Results displayed are expressed in percent inhibition of pSTAT6 signal, as compared to an isotype control, as mean + / -SEM.

[0236] Figure 5. Figure 5 is a schematic illustrating an exemplary hlL-13 administration and antiIL-13 antibody dosing schedule in C57BU6 mice. Animals in the vehicle control group received PBS intranasally every two days (Days 0-10). All other groups were administered 20 pL of 0.25 mg / mL IL-13 (5 pg / mouse) intranasally over the same period. Antibodies were administered via intraperitoneal injection on Days -1 and 5. On Day 11, serum and bronchoalveolar lavage fluid (BALF) samples were collected for measurement of total IgE and eotaxin / CCL11 levels using ELISA. Cell counts and flow cytometry were performed on BALF samples. Lung tissues were assessed for mucus overproduction and goblet cell metaplasia using Periodic acid-Schiff (PAS) staining.

[0237] Figure 6. Figures 6A-D demonstrate 6A) total serum IgE levels (ng / mL), 6B) eotaxin / CCL11 levels (pg / mL) in bronchoalveolar lavage fluid (BALF), 6C), total BAL counts, and 6D) eosinophil cell counts in mice treated with 1 mg / kg, 5 mg / kg, or 25 mg / kg of an exemplary anti-IL-13 antibody of the present disclosure (Antibody AbAE), reference antibody (Ref1), or isotype control (Isotype) and dosed with hlL-13 according to the schedule depicted in Figure 5. ns = not significant, *** p < 0.001, **** p < 0.0001.

[0238] Figure 7. Figures 7A-B depict representative images of lung sections and inflammatory endpoint histological scores collected from mice dosed according to the schedule depicted in Figure 5. Figure 7A shows micrographs of Periodic acid-Schiff (PAS)-stained lung sections collected from mice treated with 1 mg / kg, 5 mg / kg, or 25 mg / kg of an exemplary anti-IL-13 antibody of the present disclosure (Antibody AbAE), reference antibody (Ref1), or isotype control (Isotype) and dosed with hlL-13 according to the schedule depicted in Figure 5. Figure 7B shows PAS scores in lung sections collected from mice treated with 1 mg / kg, 5 mg / kg, or 25 mg / kg of an exemplary anti-IL-13 antibody of the present disclosure (Antibody AbAE), reference antibody (Ref1), or isotype control (Isotype) and dosed with hlL-13 according to the schedule depicted in Figure 5. * p < 0.05, ** p < 0.01, **** p < 0.0001.

[0239] Figure 8. Figure 8 shows a heat map with shaded cells to indicate bidirectional, blocking, non-binding interactions (response <0.1 nm) and unshaded cells to indicate bidirectional, nonblocking, binding interactions (>0.1 nm).

[0240] Figure 9. Figure 9 shows the normalized responses of Antibody AbAB, Ref2, isotype-hlgG1, and isotype-hlgG1-YTE-TM binding to a panel of recombinant human Fey receptors at 10,000 nM. Antibody binding responses were normalized to human Fey receptor capture levels and reported as normalized binding responses of one experiment.

[0241] Figure 10. Figure 10 shows the normalized responses of human C1q binding to Antibody AbAB, Ref2, isotype-hlgG4, isotype-hlgG1, and isotype-hlgG1-YTE-TM. The dotted line is positioned at 0.1 nm to indicate a non-binding interaction (< 0.1 nm) from a binding interaction (> 0.1 nm).

[0242] Figure 11. Figure 11 depicts a multiple sequence alignment of molecules that are near in sequence space (at most 4 mutations) to Antibody AbG but do not bind IL-13 with high affinity. The concatenated CDRs are shown on the top, with any mutations displayed in the alignment below corresponding to the antibody name. DETAILED DESCRIPTION

[0243] IL-13 is “type 2” cytokine that is upregulated in a variety of inflammatory diseases, such as asthma, urticaria, prurigo nodularis, nasal polyposis, and atopic dermatitis. In these type 2 inflammatory diseases IL-13 is implicated in the down regulation of epithelial derived proteins, such as filaggrin, resulting in loss of epithelial barrier integrity, tissue remodeling and subsequent increase in inflammation, pruritis, skin thickening and fibrosis as disease progresses. Despite development of treatments for IL-13 mediated diseases and disorders such treatments are inefficacious due to the requirement for repeated dosing every 2-4 weeks resulting in a lack of patient compliance.

[0244] Provided herein are anti-IL-13 antibodies or antigen binding fragments thereof (e.g., antihuman IL-13 antibodies or antigen binding fragments thereof) that have one or more advantages over conventional IL-13 antibodies including, for example, higher binding affinity, and / or an extended half-life, which may lead to reduced dosing frequency and / or improved patient compliance. Such antibodies or antigen binding fragments thereof may be useful as a monotherapy or in combination with one or more other standard of care therapies for the treatment and / or prevention of an inflammatory disease or disorder. Definitions

[0245] Definitions of certain terms to be used herein are provided. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood.

[0246] The term "Interleukin-13", or "IL-13" includes human IL-13, including the native-sequence polypeptide, isoforms, chimeric polypeptides, all homologs, fragments, and precursors of IL-13. An exemplary amino acid sequence for human IL-13 is provided in NCBI Reference Sequences: NG_012090.1 (SEQ ID NO: 161).

[0247] The term “antibody” herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, chimeric antibodies, humanized antibodies, human antibodies, and multi-specific antibodies {e.g., bispecific antibodies).

[0248] An exemplary antibody such as an IgG comprises two heavy chains (abbreviated herein as HC) and two light chains (abbreviated herein as LG). Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. Each light chain is comprised of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino terminus to carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.

[0249] The hypervariable region generally encompasses amino acid residues from about amino acid residues 27-32 (LCDR1; “L” denotes light chain), 50-52 (LCDR2) and 89-97 (LCDR3) in the light chain variable region and around about 26-33 (HCDR1; “H” denotes heavy chain), 51-57 (HCDR2), and 93-102 (HCDR3) in the heavy chain variable region; (Kabat etal., NIH. 1:103-108, 324-331; 1991) and / or those residues forming a hypervariable loop {e.g., residues 27-32 (LCDR1), 50-52 (LCDR2) and 89-97 (LCDR3) in the light chain variable region and 26-33 (HCDR1), 51-57 (HCDR2) and 93-102 (HCDR3) in the heavy chain variable region; (Chothia and Lesk, J Mol Biol. 196:901-917;1987) and / or those residues forming a hypervariable loop {e.g., residues 27-38 (CDR1), 56-65 (CDR2) and 105-117 (CDR3)) in light and heavy chain variable regions (Lefranc, The Immunologist. 7:132-136; 1999; Lefranc etal., Dev Comp Immunol. 27:5577; 2003).

[0250] The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, e.g., the individual antibodies comprising the population are identical and / or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations and / or arising during production of a monoclonal antibody preparation (e.g., variants having a C-terminal lysine deletion). In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and is not to be construed as requiring production of the antibody by any method. For example, the monoclonal antibodies to be used may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.

[0251] The term “chimeric” antibody refers to a recombinant antibody in which a portion of the heavy and / or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species, or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity. In addition, complementarity determining region grafting may be performed to alter certain properties of the antibody molecule including affinity or specificity. Typically, the variable domains are obtained from an antibody from an experimental animal (the "parental antibody"), such as a rodent, and the constant domain sequences are obtained from human antibodies, so that the resulting chimeric antibody can direct effector functions in a human subject and will be less likely to elicit an adverse immune response than the parental (e.g., mouse) antibody from which it is derived.

[0252] The term “humanized antibody” refers to an antibody that has been engineered to comprise one or more human framework regions in the variable region together with non-human (e.g., mouse, rat, or hamster) complementarity-determining regions of the heavy and / or light chain. In some embodiments, a humanized antibody comprises sequences that are entirely human except for the CDR regions. Humanized antibodies are typically less immunogenic to humans, relative to non-humanized antibodies, and thus offer therapeutic benefits in certain situations. Many examples exist of humanized antibodies and suitable techniques for their generation. See for example, Hwang etal., Methods. 36:35, 2005; Queen etal., Proc. Natl. Acad. Sci. USA. 86:10029-10033, 1989; Jones et al., Nature. 321:522-25, 1986, Riechmann et a!., Nature. 332:323-27, 1988; Verhoeyen et al., Science. 239:1534-36, 1988; Orlandi et al., Proc. Natl. Acad. Sci. USA. 86:3833-37, 1989; U.S. Pat. Nos. 5,225,539; 5,530,101; 5,585,089; 5,693,761, 5,693,762; 6,180,370; and Selick etal. (WO 90 / 07861), each of which is incorporated herein by reference in its entirety.

[0253] A “human antibody” is an antibody that possesses an amino-acid sequence corresponding to that of an antibody capable of being produced by the human genome and / or has been made using any of the techniques for making human antibodies. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues. Human antibodies can be produced using various techniques, including methods described in Cole et al., Monoclonal Antibodies and Cancer Therapy. 27:77-96, 1985; Boemer et al., J. Immuno. 147(1):86-95; 1991. See also van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5:36874; 2001. Human antibodies can be prepared by administering the antigen to a transgenic animal that has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled, e.g., immunized HuMab mice (see, e.g., Lonberg et al., Nature. 368:856-859, 1994; WO 98 / 24884; WO 94 / 25585; WO 92 / 22645; U.S. Pat. No. 5,569,825 (WO 92 / 03918); and U.S. Pat. App. No. 10 / 031,722 (WO 01 / 09187) regarding HuMab mice), xenomice (see, e.g., U.S. Pat. Nos. 5,569,825, 6,075,181 and 6,150,584 regarding XENOMOUSE™ technology).

[0254] The “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., lgG1, lgG2, lgG3, lgG4, lgA1, and lgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called a, 5, e, y, and p, respectively.

[0255] The terms “antigen-binding domain” of an antibody (or simply “binding domain”) of an antibody or similar terms refer to one or more fragments of an antibody that retain the ability to specifically bind to an antigen complex. Examples of binding fragments encompassed within the term “antigen-binding portion” of an antibody include (i) Fab fragments, monovalent fragments consisting of the VL, VH, constant light (CL) and constant heavy (CH) domains; (ii) F(ab’)2 fragments, bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) Fd fragments consisting of the VH and CH domains; (iv) Fv fragments consisting of the VL and VH domains of a single arm of an antibody, (v) dAb fragments (Ward et al., Nature. 341: 544-546; 1989), which consist of a VH domain; (vi) isolated complementarity determining regions, and (vii) combinations of two or more isolated CDRs which may optionally be joined by a synthetic linker.

[0256] The “variable domain” (V domain) or “variable region” of an antibody mediates binding and confers antigen specificity of a particular antibody. However, the variability is not evenly distributed across the 110-amino acid span of the variable domains. Instead, the V regions consist of relatively invariant stretches called framework regions of 15-30 amino acids separated by shorter regions of extreme variability referred to herein as “hypervariable regions” or CDRs that are each 9-12 amino acids long. The exact numbering and placement of the CDRs can be different among different numbering systems. However, a variable heavy and / or variable light sequence includes the associated CDRs. Accordingly, each variable heavy region includes the vhCDRs (e.g., vhCDRI (also referred to herein as HCDR1), vhCDR2 (also referred to herein as HCDR2), and vhCDR3 (also referred to herein as HCDR3)) and each variable light region includes the vICDRs (e.g., vICDRI (also referred to herein as LCDR1), vlCDR2 (also referred to herein as LCDR2), and vlCDR3 (also referred to herein as LCDR3)).

[0257] “Complementarity determining region” or “CDR” as the terms are used herein refer to short polypeptide sequences within the variable region of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. There are three CDRs (termed CDR1, CDR2, and CDR3) within each VL and each VH. Unless stated otherwise herein, CDR and framework regions are annotated according to the Kabat numbering scheme (Kabat et al., NIH. 1:103-108, 324-331; 1991).

[0258] In some embodiments, the CDRs of an antibody can be determined according to MacCallum et al., J Mol Biol. 262:732-745; 1996, herein incorporated by reference in its entirety or according to the IMGT numbering system as described in Lefranc, The Immunologist. 7:132136; 1999 and Lefranc et al., Nucleic Acids Res. ZT. 209-212;1999, each of which is herein incorporated by reference in its entirety. See also, e.g., Martin et al., Antibody Engineering. 31:422-439; 2001, herein incorporated by reference in its entirety. In some embodiments, the CDRs of an antibody can be determined according to the AbM numbering scheme, which refers to AbM hypervariable regions, which represent a compromise between the Kabat CDRs and Chothia structural loops and are used by Oxford Molecular's AbM antibody modeling software (Oxford Molecular Group, Inc.), herein incorporated by reference in its entirety.

[0259] “Framework” or “framework region” or “FR” refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4.

[0260] A “human consensus framework” is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat et al., NIH. 1:103-108, 324-331; 1991. In some embodiments, for the VL, the subgroup is subgroup kappa I as in Kabat etal., supra. In some embodiments, for the VH, the subgroup is subgroup III as in Kabat et al., supra.

[0261] The “hinge region” is generally defined as stretching from 216-238 (EU numbering) or 226251 (Kabat numbering) of human lgG1. The hinge can be further divided into three distinct regions, the upper, middle (e.g., core), and lower hinge.

[0262] The term “Fc region” herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In some embodiments, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., NIH. 1:103-108, 324-331; 1991.

[0263] An “antibody that binds to the same epitope” as a reference antibody (e.g., a reference IL-13 antibody) refers to an antibody that contacts an overlapping set of amino acid residues of the antigen as compared to the reference antibody or blocks binding of the reference antibody to its antigen in a competition assay by at least about 50%, about 50%, at least about 60%, about 60%, at least about 70%, about 70%, at least about 80%, about 80%, at least about 90%, about 90%, or more. The amino acid residues of an antibody that contact an antigen can be determined, for example, by determining the crystal structure of the antibody in complex with the antigen or by performing hydrogen / deuterium exchange. In some embodiments, residues of an antibody that are within 5 A to the antigen are considered to contact the antigen. In some embodiments, residues of an antibody that are within 4 A to the antigen are considered to contact the antigen. In some embodiments, residues of an antibody that make a non-covalent interaction with one or more residues of the antigen are considered to contact the antigen, including but not limited to hydrogen bonds, van der Waals interactions, salt bridges, Pi stacking interactions, hydrophobic interactions, or water-mediated hydrogen bonds.

[0264] In some embodiments, an antibody that binds to the same epitope as a reference antibody blocks binding of the reference antibody to its antigen in a competition assay by at least about 50%, about 50%, at least about 60%, about 60%, at least about 70%, about 70%, at least about 80%, about 80%, at least about 90%, about 90%, or more, and conversely, the reference antibody blocks binding of the antibody to its antigen in a competition assay by at least about 50%, about 50%, at least about 60%, about 60%, at least about 70%, about 70%, at least about 80%, about 80%, at least about 90%, about 90%, or more.

[0265] The term “antigen binding fragment” or “antibody fragment” refers to a molecule other than an intact antibody (e.g., a full-length antibody) that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antigen binding fragments include but are not limited to Fv, Fab, Fab’, Fab’-SH, F(ab)2; diabodies; linear antibodies; singlechain antibody molecules (e.g., scFv). Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, and a residual “Fc” fragment, a designation reflecting the ability to crystallize readily. The Fab fragment consists of an entire light (L) chain along with the variable region domain of the heavy (H) chain (VH), and the first constant domain of one heavy chain (CHI). Pepsin treatment of an antibody yields a single large F(ab)2 fragment which roughly corresponds to two disulfide linked Fab fragments having divalent antigen-binding activity and is still capable of cross-linking antigen. Fab fragments differ from Fab’ fragments by having additional few residues at the carboxy terminus of the CHI domain including one or more cysteines from the antibody hinge region. Fab’-SH is the designation herein for Fab’ in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab’)2 antigen binding fragments originally were produced as pairs of Fab’ fragments which have hinge cysteines between them. Other chemical couplings of antigen binding fragments are also known.

[0266] “Fv” consists of a dimer of one heavy- and one light-chain variable region domain in tight, non-covalent association. From the folding of these two domains emanate six hypervariable loops (3 loops each from the H and L chain) that contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody.

[0267] “Single-chain Fv” also abbreviated as “sFv” or “scFv” are antigen binding fragments that comprise the VH and VL antibody domains connected into a single polypeptide chain. The sFv 98 polypeptide may further comprise a linker (e.g., a polypeptide linker) between the VH and VL domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269- 315 (1994).

[0268] The term “multispecific antibody” is used in the broadest sense and specifically covers an antibody comprising a heavy chain variable domain (VH) and a light chain variable domain (VL), where the VH-VL unit has polyepitopic specificity (e.g., is capable of binding to two different epitopes on one biological molecule or each epitope on a different biological molecule). Such multispecific antibodies include, but are not limited to, full-length antibodies, antibodies having two or more VL and VH domains, bispecific diabodies and triabodies. “Polyepitopic specificity” refers to the ability to specifically bind to two or more different epitopes on the same or different target(s).

[0269] “Dual specificity” or “bispecificity” refers to the ability to specifically bind to two different epitopes on the same or different target(s). However, in contrast to bispecific antibodies, dualspecific antibodies have two antigen-binding arms that are identical in amino acid sequence and each Fab arm can recognize two antigens. Dual specificity allows the antibodies to interact with high affinity with two different antigens as a single Fab or IgG molecule. According to some embodiments, the multispecific antibody in an lgG1 form binds to each epitope with an affinity of 5 pM to 0.001 pM, 3 pM to 0.001 pM, 1 pM to 0.001 pM, 0.5 pM to 0.001 pM, or 0.1 pM to 0.001 pM. “Monospecific” refers to the ability to bind only one epitope. Multi-specific antibodies can have structures similar to full immunoglobulin molecules and include Fc regions, for example IgG Fc regions.

[0270] As used herein, the term "bispecific antibody" refers to a monoclonal, often human or humanized, antibody that has binding specificities for at least two different antigens. One of the binding specificities can be directed towards IL-13, the other can be for any other antigen, e.g., for a cell-surface protein, receptor, receptor subunit, tissue-specific antigen, virally derived protein, virally encoded envelope protein, bacterially derived protein, or bacterial surface protein, etc.

[0271] As used herein, the term "diabody" refers to a bivalent antibody comprising two polypeptide chains, in which each polypeptide chain includes VH and VL domains joined by a linker that is too short (e.g., a linker composed of five amino acids) to allow for intramolecular 99 association of VH and VL domains on the same peptide chain. This configuration forces each domain to pair with a complementary domain on another polypeptide chain so as to form a homodimeric structure. Accordingly, the term "triabody" refers to a trivalent antibody comprising three peptide chains, each of which contains one VH domain and one VL domain joined by a linker that is exceedingly short (e.g., a linker composed of 1-2 amino acids) to permit intramolecular association of VH and VL domains within the same peptide chain.

[0272] The term an “isolated antibody” or an “isolated antigen binding fragment” when used to describe the various antibodies or antigen binding fragments thereof provided herein, means an antibody or antigen binding fragment that has been identified and separated and / or recovered from a cell or cell culture from which it was expressed. An isolated antibody or antigen binding fragment may include variants of the antibody or antigen binding fragment having one or more co- or post-translational modifications that arise during production, purification, and / or storage of the antibody or antigen binding fragment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and can include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In some embodiments, an isolated antibody is purified to greater than 95%, 96%, 97%, 98%, or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC) approaches. For a review of methods for assessment of antibody purity, see, for example, Flatman et al., J Chromatogr. 848:79-87; 2007. In some embodiments, the antibody will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under nonreducing or reducing conditions using Coomassie blue or silver stain.

[0273] With regards to the binding of an antibody to a target molecule, the term “specific binding” or “specifically binds” or is “specific for” a particular polypeptide or protein such as IL-13 or an epitope on a particular polypeptide or protein target such as IL-13 means binding that is measurably different from a non-specific interaction. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule. For example, specific binding can be determined by competition with a control molecule that is similar to the target, for example, an excess of non-labeled target. In this case, specific binding is indicated if the binding of the labeled target to a probe is competitively inhibited by excess unlabeled target (e.g., inhibited by at least about 10%, about 10%, at least about 20%, about 20%, 100 at least about 30%, about 30%, at least about 40%, about 40%, at least about 50%, about 50%, at least about 60%, about 60%, at least about 70%, about 70%, at least about 80%, about 80%, at least about 90%, about 90%, at least about 100%, or about 10%). The term “specific binding” or “specifically binds to” or is “specific for” a particular polypeptide or an epitope on a particular polypeptide target as used herein can be exhibited, for example, by a molecule having a Ko for the target of 10-4 M or lower, alternatively 10’5 M or lower, alternatively 10’6 M or lower, alternatively 10’7 M or lower, alternatively 10’8 M or lower, alternatively 10’9 M or lower, alternatively 10’10 M or lower, alternatively 10’11 M or lower, alternatively 10-12 M or lower or a KD in the range of 10’4 M to 1045 M or 1045 M to 10’10 M or 10’7 M to 10-9 M. Affinity and KD values are inversely related. A high affinity for an antigen is measured by a low Ko value. In some embodiments, the term “specific binding” refers to binding where a molecule binds to IL-13 or to an IL-13 epitope without substantially binding to any other polypeptide or polypeptide epitope. As used herein, the term “binding” may refer to “specific binding” such that each and every occurrence of the term “binding” may be replaced with the term “specific binding.”

[0274] The term “affinity” as used herein, means the strength of the binding of an antibody to an epitope. The affinity of an antibody is given by the equilibrium dissociation constant Kd, defined as [Ab]x[Ag] / [Ab-Ag], where [Ab-Ag] is the molar concentration of the antibody-antigen complex, [Ab] is the molar concentration of the unbound antibody and [Ag] is the molar concentration of the unbound antigen. The affinity constant Ka is defined by 1 / KD. Methods for determining the affinity of monoclonal antibodies (mAbs) can be found in Harlow, etal., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory' Press, Cold Spring Harbor, N.Y., (1988), Coligan et al., Current Protocols in Immunology, Greene Publishing Assoc, and Wiley Interscience, N.Y., (1992, 1993), and Muller, Meth. Enzymol. 92:589-601; 1983, which are entirely incorporated herein by reference. One standard method for determining the affinity of mAbs is the use of surface plasmon resonance (SPR) screening (such as by analysis with a BIAcore™ SPR analytical device).

[0275] An "epitope" indicates the site or sites of interaction between an antibody and its antigen(s). As described by (Janeway, C, Jr., P. Travers, et al., (2001). Immunobiology: the immune system in health and disease. Part II, Section 3-8. New York, Garland Publishing, Inc.): "An antibody generally recognizes only a small region on the surface of a large molecule such as a protein... [Certain epitopes] are likely to be composed of amino acids from different parts of the [antigen] polypeptide chain that have been brought together by protein folding. Antigenic determinants of this kind are known as conformational or discontinuous epitopes because the 101 structure recognized is composed of segments of the protein that are discontinuous in the amino acid sequence of the antigen but are brought together in the three-dimensional structure. In contrast, an epitope composed of a single segment of polypeptide chain is termed a continuous or linear epitope" (Janeway, C. Jr., P. Travers, etal., (2001). Immunobiology: the immune system in health and disease. Part II, Section 3-8. New York, Garland Publishing, Inc.). An epitope may be a structural epitope or a functional epitope.

[0276] The term "KD", as used herein, refers to the equilibrium dissociation constant, which is obtained from the ratio of k^ to kon (e.g., kodkon) and is expressed as a molar concentration (M). Kd values for antibodies can be determined using well-established methods. Methods for determining the Kd of an antibody include biolayer interferometry (BLI) analysis, using a Fortebio Octet RED device, surface plasmon resonance, using a biosensor system such as a BIACORE® surface plasmon resonance system, or flow cytometry and Scatchard analysis.

[0277] “ECso” with respect to an agent and a particular activity (e.g., binding to a cell, inhibition of enzymatic activity, activation, or inhibition of an immune cell), refers to the efficient concentration of the agent which produces 50% of its maximum response or effect with respect to such activity. “EC100” with respect to an agent and a particular activity refers to the efficient concentration of the agent which produces its substantially maximum response with respect to such activity.

[0278] “ICso”with respect to an agent and a particular activity (e.g., binding to a cell, inhibition of enzymatic activity, activation, or inhibition of an immune cell), refers to the inhibitory concentration of the agent which inhibits half of its maximum response or effect with respect to such activity. “IC100” with respect to an agent and a particular activity refers to the inhibitory concentration of the agent which inhibits its substantially maximum response with respect to such activity.

[0279] Alignment of sequences for comparison to achieve maximal levels of identity can be readily performed by a person of ordinary skill in the art using an appropriate alignment method or algorithm. In some instances, alignment can include introduced gaps to provide for the maximal level of identity. Examples include the local homology algorithm of Smith & Waterman, Adv. Appl. Math.2:482 (1981), the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol.48:443 (1970), the search for similarity method of Pearson & Lipman, Proc. Nat’l. Acad. Sci. USA 85:2444 (1988), computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 102 575 Science Dr., Madison, Wis.), and visual inspection (see generally Ausubel et al., Current Protocols in Molecular Biology).

[0280] When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequent coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters. A commonly used tool for determining percent sequence identity is Protein Basic Local Alignment Search Tool (BLASTP) available through National Center for Biotechnology Information, National Library of Medicine, of the United States National Institutes of Health. (Altschul et al., 1990).

[0281] As used herein, the term “paratope” refers to a set of amino acid residues in an antibody or an antigen-binding fragment thereof that contribute to a binding interaction with an epitope of a target protein. The binding interaction can be a hydrogen bond, a salt bridge, a van der Waal interaction, an ionic bond, or a combination thereof. A binding interaction may be direct, or indirect, e.g., via a coordinated intermediate molecule, such as an ion or water. The residues of a paratope, in some embodiments, comprise only residues that are part of a defined CDR. In other embodiments, the residues of a paratope further comprise one or more residues that are not part of a defined CDR. In some embodiments, a paratope is oriented less than about 5.0 angstroms from an epitope on a target antigen when a polypeptide is bound to the target antigen, e.g., less than about: 4.5, 4.0, 3.5, 3.0, 2.5, 2.4, 2.3, 2.2, 2.1, 2.0, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.0 or 0.9 angstroms, or about: 0.9-5.0, 0.9-4.8.1.0-5, 1.0-4.5, 1.0-4.0, 1.0-3.5, 1.1-3.5, 1.1-3.0, 1.2-3.0, 1.2-2.5, 1.3-2.5, 1.3-2.4, 1.4-2.4, 1.4-2.3, 1.5-2.3, 1.5-2.2, 1.6-2.2, 1.6-2.1, 1.7-2.1, 1.72.0 or 1.8-2.0 angstroms, from the epitope. In some embodiments, less than all of the amino acid residues constituting a paratope (e.g., about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% of the amino acid residues) in the paratope are oriented less than about 5.0 angstroms from an epitope on a target antigen when a polypeptide is bound to the target antigen. Anti-IL-13 Antibodies and Antigen Binding Fragments Thereof

[0282] Provided herein are anti-IL-13 antibodies and antigen binding fragments thereof. In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof bind to IL-13 including, for example, human IL-13 (SEQ ID NO: 161). As used herein, the term “anti-IL-13 103 antibodies and antigen binding fragments thereof” is used interchangeably with the terms “polypeptides” or “proteins” such that the term “polypeptides” or “proteins” can replace each and every occurrence of the term “anti-IL-13 antibodies and antigen binding fragments thereof.”

[0283] The anti-IL-13 antibody and antibody fragments described herein may comprise heavy and / or light chain CDRs from AbA, AbB, AbC, AbD, AbE, AbF, AbG, AbH, AbL AbJ, AbK, AbL, AbM, AbN, AbO, or AbP. In some embodiments, the CDRs of an anti-IL-13 antibody or antigen binding fragment thereof can be determined according to the Kabat system (Kabat et al. (1971) Ann. NYAcad. Sci. 190:382-391 and, Kabat et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 913242). In other embodiments, the CDRs of an anti-IL-13 antibody or antigen binding fragment thereof can be determined according to the Chothia system, which will be referred to herein as the “Chothia CDRs” (see, eg., Chothia and Lesk, 1987, J. Mol. Biol., 196:901-917; Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948; Chothia et al., 1992, J. Mol. Biol., 227:799-817; Tramontane A et al., 1990, J. Mol. Biol. 215(1): 175-82; and U.S. Patent No. 7,709,226). In yet other embodiments, the CDRs of an anti-IL-13 antibody or antigen binding fragment thereof can be determined according to the ImMunoGeneTics (IMGT) system, which will be referred to herein as the “IMGT CDRs”, for example, as described in Lefranc, M.-P., 1999, The Immunologist, 7:132136 and Lefranc, M.-P. etal., 1999, Nucleic Acids Res., 27:209-212. In still further embodiments, the CDRs of an anti-IL-13 antibody or antigen binding fragment thereof can be determined according to the AbM system, which will be referred to herein as the “AbM CDRs,” for example as described in MacCallum et al., 1996, J. Mol. Biol., 262:732-745. See also, e.g., Martin, A., “Protein Sequence and Structure Analysis of Antibody Variable Domains,” in Antibody Engineering, Kontermann and Dubel, eds., Chapter 31, pp. 422-439, Springer-Verlag, Berlin (2001). In other embodiments, the CDRs of an anti-IL-13 antibody or antigen binding fragment thereof can be determined according to the Contact system, which will be referred to herein as the “Contact CDRs” (see, e.g., MacCallum RM et al., 1996, J Mol Biol 5: 732-745). The Contact CDRs are based on an analysis of the available complex crystal structures.

[0284] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof comprise a VH having a set of CDRs (HCDR1, HCDR2, and HCDR3) provided in Table 1. In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 comprise a VH having a set of CDRs (HCDR1, HCDR2, and HCDR3) provided in Table 1. In some embodiments, the anti-IL-13 antibody or antigen binding fragment thereof comprises a VH having 104 a set of CDRs (HCDR1, HCDR2, and HCDR3), provided in Table 1, wherein the anti-IL-13 antibody or antigen binding fragment thereof binds IL-13. For example, the anti-IL-13 antibody or antigen binding fragment thereof may comprise a set of CDRs corresponding to those CDRs in one or more of the anti-IL-13 antibodies provided in Table 1 (e.g., the CDRs of AbA, AbB, AbC, AbD, AbE, AbF, Antibody AbG, AbH, Abi, AbJ, AbK, AbL, AbM, AbN, AbO, or AbP). The anti-IL-13 antibody or antigen binding fragment thereof that binds IL-13 may also comprise a set of CDRs corresponding to those CDRs in one or more of the anti-IL-13 antibodies provided in Table 1 (e.g., the CDRs of AbA, AbB, AbC, AbD, AbE, AbF, AbG, AbH, Abi, AbJ, AbK, AbL, AbM, AbN, AbO, or AbP). For another example, the anti-IL-13 antibody or antigen binding fragment thereof may comprise a set of CDRs corresponding to those CDRs in one or more of the anti-IL-13 antibodies provided in Table 1 (e.g., the CDRs of AbA, AbB, AbC, AbD, AbE, AbF, AbG, AbH, Abi, AbJ, AbK, AbL, AbM, AbN, AbO, or AbP), wherein the anti-IL-13 antibody or antibody fragment thereof binds IL-13. TABLE 1: CDR Sequences of Anti-IL-13 Antibody Variable Heavy Chains According to Kabat Numbering Anti-IL-13 Ab HCDR1 HCDR2 HCDR3 AbA AYSVN (SEQ ID NO: 4) MIWGDGKIVYNSALKS (SEQ ID NO: 5) DGYYPYAMDN (SEQ ID NO: 6) AbB AYSVN (SEQ ID NO: 10) MIWGDGKIVYNSALKS (SEQ ID NO: 11) DGYYPYAMDN (SEQ ID NO: 12) AbC AYSVN (SEQ ID NO: 16) MIWGDGKIVYNSALKS (SEQ ID NO: 17) DGYYPYAMDY (SEQ ID NO: 18) AbD AYSVN (SEQ ID NO: 22) MIWGDGKVVYNSALKS (SEQ ID NO: 23) DGYFPYAMDN (SEQ ID NO: 24) AbE AYSVN (SEQ ID NO: 28) MIWGDGKIVYNSALKS (SEQ ID NO: 29) DGYFPYAMDN (SEQ ID NO: 30) AbF RYSVN (SEQ ID NO: 34) MIWGDAKIVYNSALKS (SEQ ID NO: 35) DGYFPYAMDN (SEQ ID NO: 36) AbG AYSVN MIWGDGKIVYNSALKS DGYFPYAMDN (SEQ ID NO: 40) (SEQ ID NO: 41) (SEQ ID NO: 42) AbH RYSVN (SEQ ID NO: 46) MIWGDGKIVYNSALKS (SEQ ID NO: 47) DGYYPYAMDN (SEQ ID NO: 48) Abi RYSVN (SEQ ID NO: 52) MIWGDGKIVYNSALKS (SEQ ID NO: 53) DGFYPYAMDN (SEQ ID NO: 54) AbJ AYSVN (SEQ ID NO: 58) MIWGDRKKVYNSALKS (SEQ ID NO: 59) DGYFPYAMDL (SEQ ID NO: 60) AbK RYSVN (SEQ ID NO: 64) MIWGDGKIVYNSALKS (SEQ ID NO: 65) DGYYPYAMDN (SEQ ID NO: 66) AbL RYSVN (SEQ ID NO: 70) MIWGDGKIVYNSALKS (SEQ ID NO: 71) DGYYPYAMDN (SEQ ID NO: 72) AbM AYSVN (SEQ ID NO: 76) MIWGDGKIVYNSALKS (SEQ ID NO: 77) DGYFPYAMDN (SEQ ID NO: 78) AbN AYSVN (SEQ ID NO: 82) MIWGDGKIVYNSALKS (SEQ ID NO: 83) DGYYPYAMDN (SEQ ID NO: 84) AbO AYSVN (SEQ ID NO: 88) MIWGDGKIVYNSALKS (SEQ ID NO: 88) DGYFPYAMDV (SEQ ID NO: 90) AbP AYSVN (SEQ ID NO: 94) MIWGDGKVVYNSALKS (SEQ ID NO: 95) DGYFPYAMDH (SEQ ID NO: 96)

[0285] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof comprise a VL having a set of CDRs (LCDR1, LCDR2, and LCDR3) as provided in Table 2. In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 comprise a VL having a set of CDRs (LCDR1, LCDR2, and LCDR3) as provided in Table 2. In some embodiments, the anti-IL-13 antibody or antigen binding fragment thereof comprises a VL having a set of CDRs (LCDR1, LCDR2, and LCDR3) wherein the anti-IL-13 antibody or antigen binding fragment thereof binds IL-13, as provided in Table 2. For example, the anti-IL-13 antibody or antigen binding fragment thereof may comprise a set of CDRs corresponding to those CDRs in one or more of the anti-IL-13 antibodies provided in Table 2 (e.g., the CDRs of AbA, AbB, AbC, AbD, AbE, AbF, AbG, AbH, Abi, AbJ, AbK, AbL, AbM, AbN, AbO, or AbP). The antibody or antigen 106 binding fragment thereof that binds IL-13 may also comprise a set of CDRs corresponding to those CDRs in one or more of the antibodies provided in Table 2 (eg., the CDRs of AbA, AbB, AbC, AbD, AbE, AbF, AbG, AbH, Abi, AbJ, AbK, AbL, AbM, AbN, AbO, or AbP). For another example, the anti-IL-13 antibody or antigen binding fragment thereof may comprise a set of CDRs corresponding to those CDRs in one or more of the anti-IL-13 antibodies provided in Table 2 (e.g., the CDRs of AbA, AbB, AbC, AbD, AbE, AbF, AbG, AbH, Abi, AbJ, AbK, AbL, AbM, AbN, AbO, or AbP), wherein the anti-IL-13 antibody or antigen binding fragment thereof binds IL-13. TABLE 2: CDR Sequences of Anti-IL-13 Antibody Variable Light Chains According to Kabat Numbering Anti-IL-13 Ab LCDR1 LCDR2 LCDR3 AbA RASKSVDSYGRSYMH (SEQ ID NO: 1) LASNLES (SEQ ID NO: 2) QQNNEDPRT (SEQ ID NO: 3) AbB RASKSVDYYGHSYMH (SEQ ID NO: 7) LASNLES (SEQ ID NO: 8) QQNNEDPRT (SEQ ID NO: 9) AbC RASKSVDYYGNSYMH (SEQ ID NO: 13) LASNLES (SEQ ID NO: 14) QQNNEDPRT (SEQ ID NO: 15) AbD RASKSVDSYGNSYMH (SEQ ID NO: 19) LASNLES (SEQ ID NO: 20) QQNNEDPRT (SEQ ID NO: 21) AbE RASKSVDSYGHSYMH (SEQ ID NO: 25) WASNLES (SEQ ID NO: 26) QQNNEDPRT (SEQ ID NO: 27) AbF RASESVDSYGNSYMH (SEQ ID NO: 31) LASNLES (SEQ ID NO: 32) QQNNEDPRT (SEQ ID NO: 33) AbG RASKSVDSYGNSYMH (SEQ ID NO: 37) LASNLES (SEQ ID NO: 38) QQNNEDPRT (SEQ ID NO: 39) AbH RASKSVDSYGNSYMH (SEQ ID NO: 43) RASNLES (SEQ ID NO: 44) QQNNEDPRT (SEQ ID NO: 45) Abi RASKSVDSYGNSYMH (SEQ ID NO: 49) LASNLES (SEQ ID NO: 50) QQNNEDPRT (SEQ ID NO: 51) AbJ RASKSVDSYGHSYMH (SEQ ID NO: 55) WASNLES (SEQ ID NO: 56) QQNNEDPRT (SEQ ID NO: 57) AbK RASQSVDSYGNSYMH (SEQ ID NO: 61) LASNLES (SEQ ID NO: 62) QQNNEDPRT (SEQ ID NO: 63) AbL RASKSVDSYGRSYMH (SEQ ID NO: 67) LASNLES (SEQ ID NO: 68) QQNNEDPRT (SEQ ID NO: 69) AbM RASKSVDYYGRSYMH (SEQ ID NO: 73) LASNLES (SEQ ID NO: 74) QQNNEDPRT (SEQ ID NO: 75) AbN RASESVDYYGHSYMH (SEQ ID NO: 79) LASNLES (SEQ ID NO: 80) QQNNEDPRT (SEQ ID NO: 81) AbO RASKSVDYYGHSYMH (SEQ ID NO: 85) LASNLES (SEQ ID NO: 86) QQNNEDPRT (SEQ ID NO: 87) AbP RASKSVDSYGNSYMH (SEQ ID NO: 91) WASNLES (SEQ ID NO: 92) QQNNEDPRT (SEQ ID NO: 93)

[0286] In some embodiments, the anti-IL-13 antibody or antigen binding fragment thereof comprises a VH having a set of CDRs (HCDR1, HCDR2, and HCDR3) as provided in Table 1, and a VL having a set of CDRs (LCDR1, LCDR2, and LCDR3) as provided in Table 2.

[0287] In some embodiments, the antibody may be a monoclonal, chimeric, bispecific, humanized, or human antibody. In some embodiments, the anti-IL-13 antibody or antigen binding fragment thereof comprises all six of the CDR regions of AbA, AbB, AbC, AbD, AbE, AbF, AbG, AbH, Abi, AbJ, AbK, AbL, AbM, AbN, AbO, or AbP.

[0288] In some embodiments, the anti-IL-13 antibody or antigen binding fragment thereof comprises a VH having a set of complementarity-determining regions (CDR1, CDR2, and CDR3) selected from the group consisting of: (i) CDR1: SEQ ID NO: 4, CDR2: SEQ ID NO: 5, CDR3: SEQ ID NO: 6; (ii) CDR1: SEQ ID NO: 10, CDR2: SEQ ID NO: 11, CDR3: SEQ ID NO: 12; (iii) CDR1: SEQ ID NO: 16, CDR2: SEQ ID NO: 17, CDR3: SEQ ID NO: 18; (iv) CDR1: SEQ ID NO: 22, CDR2: SEQ ID NO: 23, CDR3: SEQ ID NO: 24; (v) CDR1: SEQ ID NO: 28, CDR2: SEQ ID NO: 29, CDR3: SEQ ID NO: 30; (vi) CDR1: SEQ ID NO: 34, CDR2: SEQ ID NO: 35, CDR3: SEQ ID NO: 36; (vii) CDR1: SEQ ID NO: 40, CDR2: SEQ ID NO: 41, CDR3: SEQ ID NO: 42; (viii) CDR1: SEQ ID NO: 46, CDR2: SEQ ID NO: 47, CDR3: SEQ ID NO: 48; (ix) CDR1: SEQ ID NO: 52, CDR2: SEQ ID NO: 53, CDR3: SEQ ID NO: 54; (x) CDR1: SEQ ID NO: 58, CDR2: SEQ ID NO: 59, CDR3: SEQ ID NO: 60; (xi) CDR1: SEQ ID NO: 64, CDR2: SEQ ID NO: 65, CDR3: SEQ ID NO: 66; (xii) CDR1: SEQ ID NO: 70, CDR2: SEQ ID NO: 71, CDR3: SEQ ID NO: 72; (xiii) CDR1: SEQ ID NO: 76, CDR2: SEQ ID NO: 77, CDR3: SEQ ID NO: 78; (xiv) CDR1: SEQ ID NO: 82, CDR2: SEQ ID NO: 83, CDR3: SEQ ID NO: 84; (xv) CDR1: SEQ ID NO: 88, CDR2: SEQ ID NO: 89, CDR3: SEQ ID NO: 90; and (xvi) CDR1: SEQ ID NO: 94, CDR2: SEQ ID NO: 95, CDR3: SEQ ID NO: 96.

[0289] In some embodiments, the anti-IL-13 antibody or antigen binding fragment thereof comprises a VL having a set of complementarity-determining regions (CDR1, CDR2, and CDR3) selected from the group consisting of: (i) CDR1: SEQ ID NO: 1, CDR2: SEQ ID NO: 2, CDR3: SEQ ID NO: 3; (ii) CDR1: SEQ ID NO: 7, CDR2: SEQ ID NO: 8, CDR3: SEQ ID NO: 9; (iii) CDR1: SEQ ID NO: 13, CDR2: SEQ ID NO: 14, CDR3: SEQ ID NO: 15; (iv) CDR1: SEQ ID NO: 19, CDR2: SEQ ID NO: 20, CDR3: SEQ ID NO: 21; (v) CDR1: SEQ ID NO: 25, CDR2: SEQ ID NO: 26, CDR3: SEQ ID NO: 27; (vi) CDR1: SEQ ID NO: 31, CDR2: SEQ ID NO: 32, CDR3: SEQ ID NO: 33; (vii) CDR1: SEQ ID NO: 37, CDR2: SEQ ID NO: 38, CDR3: SEQ ID NO: 39; (viii) CDR1: SEQ ID NO: 43, CDR2: SEQ ID NO: 44, CDR3: SEQ ID NO: 45; (ix) CDR1: SEQ ID NO: 49, CDR2: SEQ ID NO: 50, CDR3: SEQ ID NO: 51; (x) CDR1: SEQ ID NO: 55, CDR2: SEQ ID NO: 56, CDR3: SEQ ID NO: 57; (xi) CDR1: SEQ ID NO: 61, CDR2: SEQ ID NO: 62, CDR3: SEQ ID NO: 63; (xii) CDR1: SEQ ID NO: 67, CDR2: SEQ ID NO: 68, CDR3: SEQ ID NO: 69; (xiii) CDR1: SEQ ID NO: 73, CDR2: SEQ ID NO: 74, CDR3: SEQ ID NO: 75; (xiv) CDR1: SEQ ID NO: 79, CDR2: SEQ ID NO: 80, CDR3: SEQ ID NO: 81; (xv) CDR1: SEQ ID NO: 85, CDR2: SEQ ID NO: 86, CDR3: SEQ ID NO: 87; and (xvi) CDR1: SEQ ID NO: 91, CDR2: SEQ ID NO: 92, CDR3: SEQ ID NO: 93.

[0290] In some embodiments, the anti-IL-13 antibody or antigen binding fragment thereof comprises: (a) a VH having a set of complementarity-determining regions (CDR1, CDR2, and CDR3) selected from the group consisting of: (i) CDR1: SEQ ID NO: 4, CDR2: SEQ ID NO: 5, CDR3: SEQ ID NO: 6; (ii) CDR1: SEQ ID NO: 10, CDR2: SEQ ID NO: 11, CDR3: SEQ ID NO: 12; (iii) CDR1: SEQ ID NO: 16, CDR2: SEQ ID NO: 17, CDR3: SEQ ID NO: 18; (iv) CDR1: SEQ ID NO: 22, CDR2: SEQ ID NO: 23, CDR3: SEQ ID NO: 24; (v) CDR1: SEQ ID NO: 28, CDR2: SEQ ID NO: 29, CDR3: SEQ ID NO: 30; (vi) CDR1: SEQ ID NO: 34, CDR2: SEQ ID NO: 35, CDR3: SEQ ID NO: 36; (vii) CDR1: SEQ ID NO: 40, CDR2: SEQ ID NO: 41, CDR3: SEQ ID NO: 42; (viii) CDR1: SEQ ID NO: 46, CDR2: SEQ ID NO: 47, CDR3: SEQ ID NO: 48; (ix) CDR1: SEQ ID NO: 52, CDR2: SEQ ID NO: 53, CDR3: SEQ ID NO: 54; (x) CDR1: SEQ ID NO: 58, CDR2: SEQ ID NO: 59, CDR3: SEQ ID NO: 60; (xi) CDR1: SEQ ID NO: 64, CDR2: SEQ ID NO: 65, CDR3: SEQ ID NO: 66; (xii) CDR1: SEQ ID NO: 70, CDR2: SEQ ID NO: 71, CDR3: SEQ ID NO: 72; (xiii) CDR1: SEQ ID NO: 76, CDR2: SEQ ID NO: 77, CDR3: SEQ ID NO: 78; (xiv) CDR1: SEQ ID NO: 82, CDR2: SEQ ID NO: 83, CDR3: SEQ ID NO: 84; (xv) CDR1: SEQ ID NO: 88, CDR2: SEQ ID NO: 89, CDR3: SEQ ID NO: 90; and (xvi) CDR1: SEQ ID NO: 94, CDR2: SEQ ID NO: 95, CDR3: SEQ ID NO: 96; and (b) a VL having a set of complementarity-determining regions (CDR1, CDR2, and CDR3) selected from the group consisting of: (i) CDR1: SEQ ID NO: 1, CDR2: SEQ ID NO: 2, CDR3: SEQ ID NO: 3; (ii) CDR1: SEQ ID NO: 7, CDR2: SEQ ID NO: 8, CDR3: SEQ ID NO: 9; (iii) CDR1: SEQ ID NO: 13, CDR2: SEQ ID NO: 14, CDR3: SEQ ID NO: 15; (iv) CDR1: SEQ ID NO: 19, CDR2: SEQ ID NO: 20, CDR3: SEQ ID NO: 21; (v) CDR1: SEQ ID NO: 25, CDR2: SEQ ID NO: 26, CDR3: SEQ ID NO: 27; (vi) CDR1: SEQ ID NO: 31, CDR2: SEQ ID NO: 32, CDR3: SEQ ID NO: 33; (vii) CDR1: SEQ ID NO: 37, CDR2: SEQ ID NO: 38, CDR3: SEQ ID NO: 39; (viii) CDR1: SEQ ID NO: 43, CDR2: SEQ ID NO: 44, CDR3: SEQ ID NO: 45; (ix) CDR1: SEQ ID NO: 49, CDR2: SEQ ID NO: 50, CDR3: SEQ ID NO: 51; (x) CDR1: SEQ ID NO: 55, CDR2: SEQ ID NO: 56, CDR3: SEQ ID NO: 57; (xi) CDR1: SEQ ID NO: 61, CDR2: SEQ ID NO: 62, CDR3: SEQ ID NO: 63; (xii) CDR1: SEQ ID NO: 67, CDR2: SEQ ID NO: 68, CDR3: SEQ ID NO: 69; (xiii) CDR1: SEQ ID NO: 73, CDR2: SEQ ID NO: 74, CDR3: SEQ ID NO: 75; (xiv) CDR1: SEQ ID NO: 79, CDR2: SEQ ID NO: 80, CDR3: SEQ ID NO: 81; (xv) CDR1: SEQ ID NO: 85, CDR2: SEQ ID NO: 86, CDR3: SEQ ID NO: 87; and (xvi) CDR1: SEQ ID NO: 91, CDR2: SEQ ID NO: 92, CDR3: SEQ ID NO: 93.

[0291] In some embodiments, the anti-IL-13 antibody or antigen binding fragment thereof comprises a VH and a VL having a set of complementarity-determining regions (CDR1, CDR2 and CDR3) selected from the group consisting of: (i) VH: CDR1: SEQ ID NO: 4, CDR2: SEQ ID NO: 5, CDR3: SEQ ID NO: 6, VL: CDR1: SEQ ID NO: 1, CDR2: SEQ ID NO: 2, CDR3: SEQ ID NO: 3; (ii) VH: CDR1: SEQ ID NO: 10, CDR2: SEQ ID NO: 11, CDR3: SEQ ID NO: 12,VL:CDR1: SEQ ID NO: 7, CDR2: SEQ ID NO: 8, CDR3: SEQ ID NO: 9; (iii) VH: CDR1: SEQ ID NO: 16, CDR2: SEQ ID NO: 17, CDR3: SEQ ID NO: 18, VL: CDR1: SEQ ID NO: 13, CDR2: SEQ ID NO: 14, CDR3: SEQ ID NO: 15; and (iv) VH: CDR1: SEQ ID NO: 22, CDR2: SEQ ID NO: 23, CDR3: SEQ ID NO: 24, VL: CDR1: SEQ ID NO: 19, CDR2: SEQ ID NO: 20, CDR3: SEQ ID NO: 21. (v) VH: CDR1: SEQ ID NO: 28, CDR2: SEQ ID NO: 29, CDR3: SEQ ID NO: 30, VL: CDR1: SEQ ID NO: 25, CDR2: SEQ ID NO: 26, CDR3: SEQ ID NO: 27; (v...

Claims

1. An anti-IL-13 antibody or antigen binding fragment thereof comprising:a. a light chain variable region comprising SEQ ID NO: 1 (LCDR1), SEQ ID NO: 2 (LCDR2), and SEQ ID NO: 3 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 4 (HCDR1), SEQ ID NO: 5 (HCDR2), and SEQ ID NO: 6 (HCDR3);b. a light chain variable region comprising SEQ ID NO: 7 (LCDR1), SEQ ID NO: 8 (LCDR2), and SEQ ID NO: 9 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 10 (HCDR1), SEQ ID NO: 11 (HCDR2), and SEQ ID NO: 12 (HCDR3);c. a light chain variable region comprising SEQ ID NO: 13 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 15 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 16 (HCDR1), SEQ ID NO: 17 (HCDR2), and SEQ ID NO: 18 (HCDR3);d. a light chain variable region comprising SEQ ID NO: 19 (LCDR1), SEQ ID NO: 20 (LCDR2), and SEQ ID NO: 21 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 22 (HCDR1), SEQ ID NO: 23 (HCDR2), and SEQ ID NO: 24 (HCDR3);e. a light chain variable region comprising SEQ ID NO: 25 (LCDR1), SEQ ID NO: 26 (LCDR2), and SEQ ID NO: 27 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3);f. a light chain variable region comprising SEQ ID NO: 31 (LCDR1), SEQ ID NO: 32 (LCDR2), and SEQ ID NO: 33 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 34 (HCDR1), SEQ ID NO: 35 (HCDR2), and SEQ ID NO: 36 (HCDR3);g. a light chain variable region comprising SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2), and SEQ ID NO: 39 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 40 (HCDR1), SEQ ID NO: 41 (HCDR2), and SEQ ID NO: 42 (HCDR3);h. a light chain variable region comprising SEQ ID NO: 43 (LCDR1), SEQ ID NO: 44 (LCDR2), and SEQ ID NO: 45 (LCDR3); and a heavy chain variable regioncomprising SEQ ID NO: 46 (HCDR1), SEQ ID NO: 47 (HCDR2), and SEQ ID NO: 48 (HCDR3);i. a light chain variable region comprising SEQ ID NO: 49 (LCDR1), SEQ ID NO: 50 (LCDR2), and SEQ ID NO: 51 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 52 (HCDR1), SEQ ID NO: 53 (HCDR2), and SEQ ID NO: 54 (HCDR3);j. a light chain variable region comprising SEQ ID NO: 55 (LCDR1), SEQ ID NO: 56 (LCDR2), and SEQ ID NO: 57 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 58 (HCDR1), SEQ ID NO: 59 (HCDR2), and SEQ ID NO: 60 (HCDR3);k. a light chain variable region comprising SEQ ID NO: 61 (LCDR1), SEQ ID NO: 62 (LCDR2), and SEQ ID NO: 63 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 64 (HCDR1), SEQ ID NO: 65 (HCDR2), and SEQ ID NO: 66 (HCDR3);I. a light chain variable region comprising SEQ ID NO: 67 (LCDR1), SEQ ID NO: 68 (LCDR2), and SEQ ID NO: 69 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 70 (HCDR1), SEQ ID NO: 71 (HCDR2), and SEQ ID NO: 72 (HCDR3);m. a light chain variable region comprising SEQ ID NO: 73 (LCDR1), SEQ ID NO: 74 (LCDR2), and SEQ ID NO: 75 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 76 (HCDR1), SEQ ID NO: 77 (HCDR2), and SEQ ID NO: 78 (HCDR3);n. a light chain variable region comprising SEQ ID NO: 79 (LCDR1), SEQ ID NO: 80 (LCDR2), and SEQ ID NO: 81 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 82 (HCDR1), SEQ ID NO: 83 (HCDR2), and SEQ ID NO: 84 (HCDR3);o. a light chain variable region comprising SEQ ID NO: 85 (LCDR1), SEQ ID NO: 86 (LCDR2), and SEQ ID NO: 87 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 88 (HCDR1), SEQ ID NO: 89 (HCDR2), and SEQ ID NO: 90 (HCDR3); orp. a light chain variable region comprising SEQ ID NO: 91 (LCDR1), SEQ ID NO: 92 (LCDR2), and SEQ ID NO: 93 (LCDR3); and a heavy chain variable regioncomprising SEQ ID NO: 94 (HCDR1), SEQ ID NO: 95 (HCDR2), and SEQ ID NO: 96 (HCDR3).

2. The anti-IL-13 antibody or antigen binding fragment thereof according to claim 1, wherein the light chain variable region comprises an amino acid sequence that is at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and the heavy chain variable region comprises an amino acid sequence that is at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

3. The anti-IL-13 antibody or antigen binding fragment thereof according to claim 1, wherein the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and / or the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

4. The anti-IL-13 antibody or antigen binding fragment thereof according to claim 3, wherein: a. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 97; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 98;b. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 99; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 100;c. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 101; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 102;d. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 103; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 104;e. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 105; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 106;f. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 107; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 108;g. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 109; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 110;h. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 111; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 112;i. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 113; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 114;j. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 115; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 116;k. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 117; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 118;I. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 119; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 120;m. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 121; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 122n. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 123; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 124;o. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 125; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 126; orp. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 127; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 128.

5. The anti-IL-13 antibody or antigen binding fragment thereof according to claim 1, wherein the antibody comprises a light chain comprising an amino acid sequence that is at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence that is at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or211.

6. The anti-IL-13 antibody or antigen binding fragment thereof according to claim 5, wherein the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / orthe heavychain comprises an amino acid sequence as set forth in SEQ ID NO: 130, 132, 134, 136,138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187,188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205,206, 207, 208, 209, 210, or 211.

7. The anti-IL-13 antibody or antigen binding fragment thereof according to claim 6, wherein:a. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 129;and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 130;b. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 131; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 132;c. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 133; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 134;d. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 135; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 136;e. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 137; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 138;f. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 139; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 140;g. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 142;h. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 143; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 144;i. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 145; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 146;j. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 148;k. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 149; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 150;I. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 151; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 152;m. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 154;n. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 155; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 156;o. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 157; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 158;p. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 159; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 160;q. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 182;r. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 183;s. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 184;t. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 185;u. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 186;v. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 187;w. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 188;x. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 189;y. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 190;z. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 191;aa. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 192;bb. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 193;cc. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 194;dd. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 195;ee. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 196;ff. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 197;gg. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 198;hh. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 199;ii. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 200;jj. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 201;kk. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 202;II. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 203;mm. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 204;nn. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 205;oo. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 206;pp. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 207;qq. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 208;rr. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 209;ss. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 210; ortt. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 211.

8. The anti-IL-13 antibody or antigen binding fragment thereof according to claim 1, wherein the antibody is a monoclonal antibody.

9. The anti-IL-13 antibody or antigen binding fragment thereof according to claim 1, wherein the antibody is a human antibody.

10. The anti-IL-13 antibody or antigen binding fragment thereof according to claim 1, wherein the antibody is a bispecific antibody.

11. The anti-IL-13 antibody or antigen binding fragment thereof according to claim 1, wherein the binding fragment thereof is selected from the group consisting of Fab, Fab’, F(ab’)2, Fd, Fv, scFv, a single-chain antibody, a minibody, and a diabody.

12. The anti-IL-13 antibody or antigen binding fragment thereof according to claim 11, wherein the binding fragment thereof is an scFv.

13. The anti-IL-13 antibody or antigen binding fragment thereof according to any one of claims 1 to 12 for use as a medicament.

14. A pharmaceutical composition comprising an anti-IL-13 antibody or antigen binding fragment thereof according to any one of claims 1 to 12 and a pharmaceutically acceptable carrier.

15. A nucleic acid composition comprising one or more nucleic acids encoding the light chain variable region and heavy chain variable region of claim 1.

16. An expression vector composition comprising one or more expression vectors comprising the nucleic acid composition of claim 15.

17. A host cell comprising the nucleic acid composition of claim 15 or the expression vector composition of claim 16.

18. A method of making the anti-IL-13 antibody or antigen binding fragment thereof according to claim 1 comprising culturing the host cell of claim 17 under conditions where the antibody or binding fragment thereof that binds IL-13 is expressed and recovering the antibody or binding fragment thereof that binds IL-13.

19. An anti-IL-13 antibody or antigen binding fragment thereof comprising:a1) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 1 (LCDR1), SEQ ID NO: 2 (LCDR2), and SEQ ID NO: 3 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1,2, or 3 amino acids from SEQ ID NO: 4 (HCDR1), SEQ ID NO: 5 (HCDR2), and SEQ ID NO: 6 (HCDR3);a2) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 7 (LCDR1), SEQ ID NO: 8 (LCDR2), and SEQ ID NO: 9 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 10 (HCDR1), SEQ ID NO: 11 (HCDR2), and SEQ ID NO: 12 (HCDR3);a3) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 13 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 15 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 16 (HCDR1), SEQ ID NO: 17 (HCDR2), and SEQ ID NO: 18 (HCDR3);a4) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 19 (LCDR1), SEQ ID NO: 20 (LCDR2), and SEQ ID NO: 21 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 22 (HCDR1), SEQ ID NO: 23 (HCDR2), and SEQ ID NO: 24 (HCDR3);a5) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 25 (LCDR1), SEQ ID NO: 26 (LCDR2), and SEQ ID NO: 27 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ byno more than 1, 2, or 3 amino acids from SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3);a6) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 31 (LCDR1), SEQ ID NO: 32 (LCDR2), and SEQ ID NO: 33 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 34 (HCDR1), SEQ ID NO: 35 (HCDR2), and SEQ ID NO: 36 (HCDR3);a7) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2), and SEQ ID NO: 39 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 40 (HCDR1), SEQ ID NO: 41 (HCDR2), and SEQ ID NO: 42 (HCDR3);a8) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 43 (LCDR1), SEQ ID NO: 44 (LCDR2), and SEQ ID NO: 45 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 46 (HCDR1), SEQ ID NO: 47 (HCDR2), and SEQ ID NO: 48 (HCDR3);a9) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 49 (LCDR1), SEQ ID NO: 50 (LCDR2), and SEQ ID NO: 51 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 52 (HCDR1), SEQ ID NO: 53 (HCDR2), and SEQ ID NO: 54 (HCDR3);a10) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 55 (LCDR1), SEQ ID NO: 56 (LCDR2), and SEQ ID NO: 57 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 58 (HCDR1), SEQ ID NO: 59 (HCDR2), and SEQ ID NO: 60 (HCDR3);a11) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 61 (LCDR1), SEQ ID NO: 62 (LCDR2), and SEQ ID NO: 63 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 64 (HCDR1), SEQ ID NO: 65 (HCDR2), and SEQ ID NO: 66 (HCDR3);a12) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 67 (LCDR1), SEQ ID NO: 68 (LCDR2), and SEQ ID NO: 69 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 70 (HCDR1), SEQ ID NO: 71 (HCDR2), and SEQ ID NO: 72 (HCDR3);a13) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 73 (LCDR1), SEQ ID NO: 74 (LCDR2), and SEQ ID NO: 75 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 76 (HCDR1), SEQ ID NO: 77 (HCDR2), and SEQ ID NO: 78 (HCDR3);a14) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 79 (LCDR1), SEQ ID NO: 80 (LCDR2), and SEQ ID NO: 81 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 82 (HCDR1), SEQ ID NO: 83 (HCDR2), and SEQ ID NO: 84 (HCDR3);a15) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 85 (LCDR1), SEQ ID NO: 86 (LCDR2), and SEQ ID NO: 87 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 88 (HCDR1), SEQ ID NO: 89 (HCDR2), and SEQ ID NO: 90 (HCDR3); ora16) light chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 91 (LCDR1), SEQ ID NO: 92 (LCDR2), and SEQ ID NO: 93 (LCDR3); and heavy chain CDRs comprising amino acid sequences that differ by no more than 1, 2, or 3 amino acids from SEQ ID NO: 94 (HCDR1), SEQ ID NO: 95 (HCDR2), and SEQ ID NO: 96 (HCDR3);orb1) a light chain variable region comprising an amino acid sequence at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; andb2) a heavy chain variable region comprising an amino acid sequence at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128,wherein the LCDR1 does not include SEQ ID NO: 162 (RASKSVDSYGNSFMH).

20. The anti-IL-13 antibody or antigen binding fragment thereof according to claim 19, wherein:a. LCDR1 comprises a serine (S) at amino acid position 27D and an arginine (R) at amino acid position 30;b. LCDR1 comprises a tyrosine (Y) at amino acid position 27D and a histidine (H) at amino acid position 30;c. LCDR1 comprises a tyrosine (Y) at amino acid position 27D and an asparagine (N) at amino acid position 30; ord. LCDR1 comprises a serine (S) at amino acid position 27D and a tyrosine (Y) at amino acid position 32, wherein the amino acid positions are based on Kabat numbering.

21. An anti-IL-13 antibody or antigen binding fragment thereof comprising a light chain variable region and a heavy chain variable region,wherein the light chain variable region is at least 95% identical to SEQ ID NO: 97, 99, 101, or 103; andwherein the heavy chain variable region is at least 95% identical to SEQ ID NOs: SEQ ID NO: 98, 100, 102, or 104,provided that when serine (S) is present at amino acid position 27D then arginine (R) is present at amino acid position 30 or tyrosine (Y) is present at amino acid position 32, and when asparagine (N) is present at amino acid position 30 then tyrosine (Y) is present at amino acid position 27D, wherein the amino acid positions are based on Kabat numbering.

22. The anti-IL-13 antibody or antigen binding fragment thereof according to claim 19 or 21, wherein the antibody is a monoclonal antibody.

23. The anti-IL-13 antibody or antigen binding fragment thereof according to claim 19 or 21, wherein the antibody is a human antibody.

24. The anti-IL-13 antibody or antigen binding fragment thereof according to claim 19 or 21, wherein the antibody is a bispecific antibody.

25. The anti-IL-13 antibody or antigen binding fragment thereof according to claim 19 or 21, wherein the binding fragment thereof is selected from the group consisting of Fab, Fab’, F(ab’)2, Fd, Fv, scFv, a single-chain antibody, a minibody, and a diabody.

26. The anti-IL-13 antibody or antigen binding fragment thereof according to claim 25, wherein the binding fragment thereof is an scFv.

27. The anti-IL-13 antibody or antigen binding fragment thereof according to any one of claims 19 to 26 for use as a medicament.

28. A pharmaceutical composition comprising an anti-IL-13 antibody or antigen binding fragment thereof according to any one of claims 19 to 26 and a pharmaceutically acceptable carrier.

29. A nucleic acid composition comprising one or more nucleic acids encoding the light chain variable region and heavy chain variable region of claim 19 or 21.

30. An expression vector composition comprising one or more expression vectors comprising the nucleic acid composition of claim 29.

31. A host cell comprising the nucleic acid composition of claim 29 or the expression vector composition of claim 30.

32. A method of making the anti-IL-13 antibody or antigen binding fragment thereof according to claim 19 or 21 comprising culturing the host cell of claim 31 under conditions where the antibody or binding fragment thereof that binds IL-13 is expressed and recovering the antibody or binding fragment thereof that binds IL-13.

33. A method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective dose of an anti-IL-13 antibody or antigen binding fragment thereof, wherein the IL-13 antibody or antigen binding fragment thereof comprises:a. a light chain variable region comprising SEQ ID NO: 1 (LCDR1), SEQ ID NO: 2 (LCDR2), and SEQ ID NO: 3 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 4 (HCDR1), SEQ ID NO: 5 (HCDR2), and SEQ ID NO: 6 (HCDR3);b. a light chain variable region comprising SEQ ID NO: 7 (LCDR1), SEQ ID NO: 8 (LCDR2), and SEQ ID NO: 9 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 10 (HCDR1), SEQ ID NO: 11 (HCDR2), and SEQ ID NO: 12 (HCDR3);c. a light chain variable region comprising SEQ ID NO: 13 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 15 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 16 (HCDR1), SEQ ID NO: 17 (HCDR2), and SEQ ID NO: 18 (HCDR3);d. a light chain variable region comprising SEQ ID NO: 19 (LCDR1), SEQ ID NO: 20 (LCDR2), and SEQ ID NO: 21 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 22 (HCDR1), SEQ ID NO: 23 (HCDR2), and SEQ ID NO: 24 (HCDR3);e. a light chain variable region comprising SEQ ID NO: 25 (LCDR1), SEQ ID NO: 26 (LCDR2), and SEQ ID NO: 27 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3);f. a light chain variable region comprising SEQ ID NO: 31 (LCDR1), SEQ ID NO: 32 (LCDR2), and SEQ ID NO: 33 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 34 (HCDR1), SEQ ID NO: 35 (HCDR2), and SEQ ID NO: 36 (HCDR3);g. a light chain variable region comprising SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2), and SEQ ID NO: 39 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 40 (HCDR1), SEQ ID NO: 41 (HCDR2), and SEQ ID NO: 42 (HCDR3);h. a light chain variable region comprising SEQ ID NO: 43 (LCDR1), SEQ ID NO: 44 (LCDR2), and SEQ ID NO: 45 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 46 (HCDR1), SEQ ID NO: 47 (HCDR2), and SEQ ID NO: 48 (HCDR3);i. a light chain variable region comprising SEQ ID NO: 49 (LCDR1), SEQ ID NO: 50 (LCDR2), and SEQ ID NO: 51 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 52 (HCDR1), SEQ ID NO: 53 (HCDR2), and SEQ ID NO: 54 (HCDR3);j. a light chain variable region comprising SEQ ID NO: 55 (LCDR1), SEQ ID NO: 56 (LCDR2), and SEQ ID NO: 57 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 58 (HCDR1), SEQ ID NO: 59 (HCDR2), and SEQ ID NO: 60 (HCDR3);k. a light chain variable region comprising SEQ ID NO: 61 (LCDR1), SEQ ID NO: 62 (LCDR2), and SEQ ID NO: 63 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 64 (HCDR1), SEQ ID NO: 65 (HCDR2), and SEQ ID NO: 66 (HCDR3);I. a light chain variable region comprising SEQ ID NO: 67 (LCDR1), SEQ ID NO: 68 (LCDR2), and SEQ ID NO: 69 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 70 (HCDR1), SEQ ID NO: 71 (HCDR2), and SEQ ID NO: 72 (HCDR3);m. a light chain variable region comprising SEQ ID NO: 73 (LCDR1), SEQ ID NO: 74 (LCDR2), and SEQ ID NO: 75 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 76 (HCDR1), SEQ ID NO: 77 (HCDR2), and SEQ ID NO: 78 (HCDR3);n. a light chain variable region comprising SEQ ID NO: 79 (LCDR1), SEQ ID NO: 80 (LCDR2), and SEQ ID NO: 81 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 82 (HCDR1), SEQ ID NO: 83 (HCDR2), and SEQ ID NO: 84 (HCDR3);o. a light chain variable region comprising SEQ ID NO: 85 (LCDR1), SEQ ID NO: 86 (LCDR2), and SEQ ID NO: 87 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 88 (HCDR1), SEQ ID NO: 89 (HCDR2), and SEQ ID NO: 90 (HCDR3); orp. a light chain variable region comprising SEQ ID NO: 91 (LCDR1), SEQ ID NO: 92 (LCDR2), and SEQ ID NO: 93 (LCDR3); and a heavy chain variable region comprising SEQ ID NO: 94 (HCDR1), SEQ ID NO: 95 (HCDR2), and SEQ ID NO: 96 (HCDR3).

34. The method of claim 33, wherein the disease or disorder is selected from the group consisting of: asthma (including, but not limited to, mild asthma, mild to moderate asthma, moderate asthma, moderate to severe asthma, and / or severe asthma), allergic asthma, allergen-induced airway obstruction due to asthma and / or allergic asthma, atopic dermatitis (including, but not limited to, mild atopic dermatitis, mild to moderate atopic dermatitis, moderate atopic dermatitis, moderate-to-severe, and / or severe atopic dermatitis), eczema, acute urticaria, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), chronic obstructive airway disease, emphysema, chronic bronchitis, pulmonary fibrosis, systemic sclerosis, scleroderma, cryptogenic fibrosing alveolitis, usual interstitial pneumonitis, idiopathic interstitial pneumonitis, wound, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SS), ulcerative colitis (UC), type 1 diabetes (T1D), sjogren's syndrome (SS), prurigo nodularis, nasal polyposis, recurrent urticaria, aspergillosis, bullous pemphigoid, chronic sinusitis, alopecia areata, hay fever, pemphigus, allergic rhinitis, psoriasis, rosacea, allergic drug reactions, allergic reactions, anaphylaxis, acne, food allergies, inflammatory bowel disease (IBS), Crohn’s disease, ulcerative colitis, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis, eosinophilic colitis, eosinophilic gastritis, eosinophilic cystitis, eosinophilic fasciitis, eosinophilic pustular folliculitis, eosinophilic granulomatosis, eosinophilic polyangiitis, Churg-Strauss syndrome, biliary cancer, brain cancer, breast cancer, colorectal cancer, genitourinary cancer, head and neck cancer, liver cancer, Hodgkin's lymphoma, esophageal cancer, pancreatic cancer, prostate cancer, renal cancer, Kaposi's sarcoma, sinusitis, or chronic urticaria.

35. The method of claim 33, wherein the light chain variable region comprises an amino acid sequence that is at least 90%, at least 95%, or at least 99% identical to in SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and the heavy chain variable region comprises an amino acid sequence that is at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

36. The method of claim 33, wherein the light chain variable region comprises an amino acid sequence assetforth in SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, or 127; and / or the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, or 128.

37. The method of claim 36, wherein:a. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 97; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 98;b. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 99; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 100;c. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 101; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 102;d. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 103; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 104;e. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 105; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 106;f. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 107; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 108;g. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 109; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 110;h. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 111; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 112;i. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 113; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 114;j. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 115; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 116;k. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 117; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 118;I. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 119; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 120;m. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 121; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 122n. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 123; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 124;o. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 125; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 126; orp. the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 127; and the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 128.

38. The method of claim 33, wherein the antibody comprises a light chain comprising an amino acid sequence that is at least 90%, at least 95%, or at least 99% identical to SEQ ID NO:129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or a heavy chain comprising an amino acid sequence that is at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

39. The method of claim 38, wherein the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; and / or the heavy chain comprises an amino acid sequence as set forthin SEQ ID NO: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158,160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198,199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

40. The method of claim 39, wherein:a. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 129; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 130;b. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 131; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 132;c. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 133; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 134;d. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 135; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 136;e. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 137; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 138;f. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 139; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 140;g. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 142;h. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 143; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 144;i. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 145; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 146;j. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 148;k. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 149; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 150;I. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 151; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 152;m. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 154;n. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 155; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 156;o. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 157; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 158;p. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 159; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 160;q. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 182;r. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 183;s. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 184;t. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 185;u. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 186;v. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 187;w. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 188;x. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 189;y. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 190;z. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 191;aa. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 192;bb. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 193;cc. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 194;dd. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 195;ee. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 196;ff. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 197;gg. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 198;hh. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 199;ii. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 200;jj. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 201;kk. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 202;II. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 203;mm. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 204;nn. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 205;oo. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 206;pp. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 207;qq. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 208;rr. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 153; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 209;ss. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 147; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 210; ortt. the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 141; and the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 211.

41. The method of any of claims 33-40, wherein the antibody is a monoclonal antibody.

42. The method of any of claims 33-40, wherein the antibody is a human antibody.

43. The method of any of claims 33-40, wherein the antibody is a bispecific antibody.

44. The method of any of claims 33-40, wherein the binding fragment thereof is selected fromthe group consisting of Fab, Fab’, F(ab’)2, Fd, Fv, scFv, a single-chain antibody, a minibody, and a diabody.

45. The method of claim 44, wherein the binding fragment thereof is an scFv.

46. A computer-implemented method comprising:scoring a polypeptide comprising an amino acid sequence with a computationally binding optimized (CBO) model for a functional property relating to modulating the activity of a target molecule, the CBO model:for each amino acid position of the amino acid sequence of the polypeptide, calculating a plurality of energy scores, the energy scores based on the amino acid at a given position in the amino acid sequence,adding each energy score calculated to an array,generating a normalized sum of the energy scores for each position, and generating a score of the polypeptide by summing each energy score calculated, the score representing the functional property of the polypeptide, the functional property relating to the polypeptide modulating the activity of the target molecule.

47. The computer-implemented method of Claim 46, further comprising:calculating a logarithm of each energy score calculated;wherein summing each energy score calculated is performed by summing the logarithms of each energy score calculated;wherein the energy scores are further calculated based on having substituted the amino acid at the given position in the amino acid sequence with each of a plurality of different amino acids.

48. The computer-implemented method of any of Claims 46-47, wherein scoring the polypeptide using the CBO model is implementable by the script of Appendix A, and the CBO model is substantially similar to the table of Appendix B.

49. The method of any of Claims 46-48, wherein the functional property is at least one of:a binding affinity for an interleukin-13 (IL-13) polypeptide characterized by a KD of 10 pM or less (optionally, as measured by KinExA);a binding specificity for the IL-13 polypeptide;a neutralizing activity against the IL-13 polypeptide (optionally, a full-length human IL-13); oran inhibitory activity against IL-13-mediated signaling, or a combination of the foregoing.

50. The method of Claim 49, wherein the target molecule is interleukin-13 (IL-13), and the functional property of the relating to the polypeptide modulates the activity of the IL-13.

51. A system comprising:a processor; anda memory with computer code instructions stored thereon, the processor and the memory, with the computer code instructions, being configured to cause the system to:score a polypeptide comprising an amino acid sequence with a CBO model for a functional property relating to modulating the activity of a target molecule, the CBO model: for each amino acid position of the amino acid sequence of the polypeptide, calculating a plurality of energy scores, the energy scores based on the amino acid at a given position in the amino acid sequence,add each energy score calculated to an array,generate a normalized sum of the energy scores for each position, andgenerate a score of the amino acid sequence by summing each energy score calculated, the score representing a functional property of the polypeptide, the functional property relating to the polypeptide modulating the activity of the target molecules.

52. The system of Claim 51, wherein the instructions are further configured to cause the system to calculate a logarithm of each energy score calculated;wherein summing each energy score calculated is performed by summing the logarithms of each energy score calculated;wherein the energy scores are further based on having substituted the amino acid at the given position in the amino acid sequence with each of a plurality of different amino acids.

53. The system of any of Claims 51-52, wherein scoring the polypeptide using the CBO model is implemented by the script of Appendix A and wherein the CBO model is substantially similar to the table of Appendix B.

54. The system of any of Claims 51-53 wherein the functional property is at least one of:a binding affinity for an interleukin-13 (IL-13) polypeptide characterized by a Kd of 10 pM or less (optionally, as measured by KinExA);a binding specificity for the IL-13 polypeptide;a neutralizing activity against the IL-13 polypeptide (optionally, a full-length human IL-13); oran inhibitory activity against IL-13-mediated signaling, or a combination of the foregoing.

55. The method of Claim 54, wherein the target molecule is interleukin-13 (IL-13), and the functional property of the relating to the polypeptide modulates the activity of the IL-13.

56. A polypeptide that specifically binds an interleukin-13 (IL-13):wherein the polypeptide comprises an amino acid sequence that is assigned a score above a predetermined threshold by a computationally binding optimized (CBO) model upon scoring the amino acid sequence of the polypeptide.

57. The polypeptide of Claim 56, wherein the polypeptide is scorable by the script of Computer Program Listing Appendix A and wherein the CBO model is calculated by a table substantially similar to that of Computer Program Listing Appendix B and wherein the polypeptide is assigned the score that is calculated using the Computer Program Listing Appendix B;wherein the polypeptide is assigned the score by a script substantially similar to Computer Program Listing Appendix A, the script employing the CBO model substantially similar to the table of Computer Program Listing Appendix B, wherein the polypeptide has a logarithmic score of at least about: -1.7, -1.0, -0.5, 0, 0.5, 1, 1.5, 1.8, 2.0, and 3.0.

58. The polypeptide of any of Claims 56-57, wherein the polypeptide has one or more properties selected from:a binding affinity for an interleukin-13 (IL-13) polypeptide characterized by a KD of 10 pM or less (optionally, as measured by KinExA);a binding specificity for the IL-13 polypeptide;a neutralizing activity against the IL-13 polypeptide (optionally, a full-length human IL-13); oran inhibitory activity against IL-13-mediated signaling,or a combination of the foregoing.

59. The polypeptide of any of Claims 56-58, wherein the CBO model outputs a score that is equal to or above a score from the CBO model of one or more of a reference polypeptide that comprises a VL and VH pair selected from:SEQ ID NO: 97 and SEQ ID NO: 98 (AbA);SEQ ID NO: 99 and SEQ ID NO: 100 (AbB);SEQ ID NO: 101 and SEQ ID NO: 102 (AbC);SEQ ID NO: 103 and SEQ ID NO: 104 (AbD);SEQ ID NO: 105 and SEQ ID NO: 106 (AbE);SEQ ID NO: 107 and SEQ ID NO: 108 (AbF);SEQ ID NO: 109 and SEQ ID NO: 110 (AbG);SEQ ID NO: 111 and SEQ ID NO: 112 (AbH);SEQ ID NO: 113 and SEQ ID NO: 114 (Abi);SEQ ID NO: 115 and SEQ ID NO: 116 (AbJ);SEQ ID NO: 117 and SEQ ID NO: 118 (AbK);SEQ ID NO: 119 and SEQ ID NO: 120 (AbL);SEQ ID NO: 121 and SEQ ID NO: 122 (AbM);SEQ ID NO: 123 and SEQ ID NO: 124 (AbN);SEQ ID NO: 125 and SEQ ID NO: 126 (AbO); orSEQ ID NO: 127 and SEQ ID NO: 128 (AbP).

60. The polypeptide of any of Claims 56-59, wherein the polypeptide does not comprise a heavy chain comprising SEQ ID NO: 179 or 181 and a light chain comprising SEQ ID NO: 178 or 180.

61. A polypeptide: wherein the polypeptide comprises an amino acid sequence that is assigned a score above a predetermined threshold by a computationally binding optimized (CBO) model upon scoring the amino acid sequence of the polypeptide.

62. A polypeptide that binds human interleukin-13 (IL-13), wherein the polypeptide is designed by a method comprising:generating a polypeptide sequence with a CBO model;verifying the generated polypeptide sequence using the CBO model by:for each amino acid position of the polypeptide sequence, calculating a plurality of energy scores, the energy scores based on having substituted the amino acid at a given position in the polypeptide sequence with each of a plurality of different amino acids,adding each energy score calculated to an array,generating a normalized sum of the energy scores for each position, calculating a logarithm of each energy score calculated, andgenerating a score of the polypeptide sequence by summing the logarithms of each energy score calculated, the score representing a functional property of the polypeptide’s ability to bind to human IL-13.

Images